[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 207
1. Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant; 2007 Jan;39(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
  • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma.
  • We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n=61) or primary refractory (n=6) Hodgkin's lymphoma.
  • In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS.
  • LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115062.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


2. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL: Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant; 2008 Sep;14(9 Suppl):8-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
  • For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients.
  • In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs).
  • The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years.
  • Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
  • Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. National Health Programs
  • [MeSH-minor] Adult. Aged. Hematologic Neoplasms / therapy. History, 20th Century. History, 21st Century. Humans. Middle Aged. Registries. Survival Rate. Tissue Donors. Transplantation, Homologous. United States

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721775.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


3. Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L: A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol; 2008 May;83(5):349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias.
  • CD5-negative chronic B cell lymphoproliferative disorders in leukemic phase (B-CLPD) are heterogeneous and relatively uncommon pathologies that often lack a histopathological definition because of the absence of accessible pathological tissue.
  • A combined clinical, histological, cytomorphological, immunophenotypical, and cytogenetic diagnostic approach allowed the complete classification of only a minority of patients as being affected by splenic marginal zone or lymphoplasmacytic lymphoma; the majority of cases remained unclassifiable.
  • Multivariate analysis showed that the clinicohematological variables adversely related to overall survival were serum LDH levels and age, whereas high serum LDH levels, hemoglobin levels of <11 g/dl, and splenomegaly related to treatment-free time (in "wait and see" cases); only splenomegaly related to time to progression (in treated patients).
  • In conclusion, our retrospective study describes the clinical features and variables related to evolution in a large group of patients with CD5/CD10-negative chronic B-cell lymphoid leukemias and underlines the fact that a probable lymphoplasmacytic or marginal zone normal cell origin can be supposed in such leukemic forms, but never surely demonstrated.
  • [MeSH-major] Antigens, CD / analysis. Antigens, Neoplasm / analysis. B-Lymphocyte Subsets / chemistry. Immunophenotyping. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Neoplastic Stem Cells / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Flow Cytometry. Follow-Up Studies. Humans. Karyotyping. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoproliferative Disorders / classification. Male. Middle Aged. Retrospective Studies. Splenic Neoplasms / diagnosis. Splenic Neoplasms / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Am J Hematol. 2008 May;83(5):347-8 [18383327.001]
  • (PMID = 18186522.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


Advertisement
4. Liu CY, Sims-McCallum RP, Schiffer CA: A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res; 2005 Apr;29(4):463-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The levels remained below 4 mg/dL throughout the administration of chemotherapy for up to 96 h.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hyperuricemia / drug therapy. Leukemia / drug therapy. Lymphoma / drug therapy. Urate Oxidase / therapeutic use
  • [MeSH-minor] Adult. Aged. Child. Humans. Infant. Middle Aged. Recombinant Proteins / therapeutic use. Uric Acid / blood

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725482.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


5. Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I: Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm; 2005 Aug 14;2005(3):171-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serum concentrations of TNF-alpha, IL-1beta, sIL-2R, IL-6, IL-8, and CRP (18.6 +/- 3.7 pg/mL, 10.1 +/- 2.8 pg/mL, 730 +/- 220 U/mL, 11.4 +/- 3.3 pg/mL, 23.9 +/- 8.3 pg/mL, and 49.9 +/- 19.5 mg/dL, resp) were significantly higher in newly diagnosed MM patients than in healthy controls (P < .0001).
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):21-8 [11707866.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2584-92 [11971193.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):41-6 [12542441.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):34-42 [12631257.001]
  • [Cites] Cancer. 2003 May 15;97(10):2440-52 [12733143.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):455-7 [12845688.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3368-75 [15021914.001]
  • [Cites] Cytokine. 2004 May 21;26(4):145-8 [15149630.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • [Cites] Curr Hematol Rep. 2004 Jul;3(4):249-56 [15217554.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):161-7 [15133489.001]
  • [Cites] BioDrugs. 2004;18(4):269-78 [15244502.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):475-86 [15287939.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3085-90 [15353339.001]
  • [Cites] Clin Exp Immunol. 1991 Jun;84(3):429-34 [2044221.001]
  • [Cites] Clin Exp Immunol. 1993 Apr;92(1):27-31 [8467562.001]
  • [Cites] J Leukoc Biol. 1995 May;57(5):752-62 [7539029.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):52-6 [8907203.001]
  • [Cites] Eur J Clin Invest. 1998 Aug;28(8):679-86 [9767364.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):350-7 [10050719.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1117-25 [10626139.001]
  • [Cites] Annu Rev Immunol. 2000;18:217-42 [10837058.001]
  • [Cites] Eur J Haematol. 2000 Feb;64(2):121-9 [10997332.001]
  • [Cites] Semin Hematol. 2001 Apr;38(2 Suppl 3):15-20 [11309704.001]
  • (PMID = 16106104.001).
  • [ISSN] 0962-9351
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Receptors, Interleukin-2; 0 / Tumor Necrosis Factor-alpha; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 9007-41-4 / C-Reactive Protein; VAD protocol
  • [Other-IDs] NLM/ PMC1526466
  •  go-up   go-down


6. Russo MJ, Martens TP, Hong KN, Colman DL, Voleti VB, Smith CR Jr, Argenziano M: Minimally invasive versus standard approach for excision of atrial masses. Heart Surg Forum; 2007;10(1):E50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue diagnosis of the masses resected included myxoma (n = 24), fibroblastoma (n = 3), B-cell lymphoma (n = 1), and other benign masses (n = 6).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162403.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Tay L, Duncan E, Singhal D, Al-Qunfoidi R, Coghlan D, Jaksic W, Szabo F, McRae S, Lloyd J: Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost; 2009 Nov;35(8):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report summarizes the experience related to AH from a large Australian hemophilia center based in South Australia.
  • The incidence in South Australia was 1.20 cases per million/year with a median age of 78 years with an approximately equivalent sex ratio (12 males versus 13 females); median FVIII and inhibitor titer were 2.5 IU/dL and 11.0 BU/mL, respectively.
  • Rituximab was used in six patients for high-titer inhibitor, second relapse, two life-threatening bleeds, underlying lymphoma, and steroid intolerance, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Azathioprine / therapeutic use. Factor VIII / immunology. Factor VIIa / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Male. Middle Aged. Recombinant Proteins / therapeutic use. Recurrence. Retrospective Studies. Rituximab. South Australia / epidemiology. Steroids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Acquired Hemophilia.
  • Genetic Alliance. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169513.001).
  • [ISSN] 1098-9064
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Immunosuppressive Agents; 0 / Recombinant Proteins; 0 / Steroids; 0 / recombinant FVIIa; 4F4X42SYQ6 / Rituximab; 9001-27-8 / Factor VIII; EC 3.4.21.21 / Factor VIIa; MRK240IY2L / Azathioprine
  • [Number-of-references] 16
  •  go-up   go-down


8. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol; 2010 Mar 10;28(8):1408-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival.
  • PATIENTS AND METHODS Eligible patients had measurable disease (immunoglobulin M monoclonal protein > 1,000 mg/dL with > 10% marrow involvement or nodal masses > 2 cm), a platelet count more than 75,000 x 10(6)/L, a neutrophil count more than 1,000 x 10(6)/L, and a creatinine and bilirubin less than 2 x the laboratory upper limit of normal.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Biomarkers, Pharmacological / blood. Drug-Related Side Effects and Adverse Reactions. Everolimus. Female. Humans. Immunoglobulin M / blood. Male. Middle Aged. Recurrence. Survival Analysis. Tomography, X-Ray Computed


9. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford); 2010 Feb;49(2):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, diffusing capacity of carbon monoxide (DL(CO)) increased significantly in the RTX group compared with baseline (mean +/- s.d.: 52.25 +/- 20.71 vs 62 +/- 23.21, at baseline vs 1-year respectively, P = 0.017).
  • The median percentage of improvement of DL(CO) in the RTX group was 19.46%, whereas that of deterioration in the control group was 7.5% (P = 0.023).
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / drug effects. Biopsy. Cell Adhesion Molecules / metabolism. Collagen / metabolism. Drug Administration Schedule. Humans. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / physiopathology. Lymphocyte Depletion / methods. Middle Aged. Respiratory Function Tests / methods. Rituximab. Skin / immunology. Skin / metabolism. Skin / pathology. Tomography, X-Ray Computed. Vital Capacity / drug effects

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1991 Oct;18(10):1520-8 [1765976.001]
  • [Cites] Arch Intern Med. 1993 Jun 14;153(11):1337-42 [8507124.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):559-62 [9492775.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220 [10421308.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • [Cites] J Rheumatol. 2005 May;32(5):832-40 [15868618.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4885-91 [15746077.001]
  • [Cites] Curr Opin Rheumatol. 2005 Nov;17(6):746-51 [16224253.001]
  • [Cites] Transplantation. 2006 Feb 27;81(4):573-82 [16495806.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Drugs. 2006;66(8):1041-57 [16789791.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2655-66 [16790698.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2667-76 [16790699.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):1005-8 [16490756.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Rheumatology (Oxford). 2006 Dec;45(12):1572 [16998235.001]
  • [Cites] Ann Rheum Dis. 2003 Sep;62(9):904-5 [12922969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24 [14530402.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1721-33 [15188347.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1918-27 [15188368.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):641-50 [15277237.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Mol Immunol. 2004 Nov;41(12):1123-33 [15482848.001]
  • [Cites] Arthritis Rheum. 1980 May;23(5):581-90 [7378088.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85 [17133253.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3962-70 [17133610.001]
  • [Cites] Rheumatol Int. 2007 Feb;27(4):357-61 [17021713.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):442-5 [16899504.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):66-73 [17275413.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):349-60 [17448966.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):623-4 [17454609.001]
  • [Cites] Ann Rheum Dis. 2007 Jul;66(7):966-9 [17234649.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1388-96 [17452515.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3167-8 [17763433.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34 [17717203.001]
  • [Cites] Nephrology (Carlton). 2007 Dec;12(6):553-8 [17995580.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):552-3 [18281368.001]
  • [Cites] Arthritis Rheum. 2009 Feb;60(2):578-83 [19180481.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):193-7 [19103636.001]
  • [Cites] Arthritis Care Res. 1991 Mar;4(1):27-31 [11188583.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34 [11759059.001]
  • [CommentIn] Rheumatology (Oxford). 2010 Feb;49(2):201-2 [20032221.001]
  • (PMID = 19447770.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cell Adhesion Molecules; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2806066
  •  go-up   go-down


10. Diamond C, Taylor TH, Im T, Anton-Culver H: Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma; 2006 Sep;47(9):1822-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
  • We used the San Diego/Orange County cancer registry to identify 64 cases of systemic non-Hodgkin's lymphoma (NHL) with AIDS who received highly active antiretroviral therapy (HAART) at the time of NHL diagnosis or thereafter and 64 NHL controls without AIDS, matched on age, sex, race, time of NHL diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).
  • Thirty-three percent of cases had high grade histology versus 11% of controls (p < 0.01); 69% had baseline hemoglobin <13 g/dL versus 35% controls (p < 0.001) and 21% had baseline neutrophils <2,000/mcl versus 4% of controls (p < 0.001).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Case-Control Studies. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


11. Burgoyne LL, Anghelescu DL, Tamburro RF, De Armendi AJ: A pediatric patient with a mediastinal mass and pulmonary embolus. Paediatr Anaesth; 2006 Apr;16(4):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When anesthetizing a patient with an anterior mediastinal mass, sudden hypoxaemia and cardiovascular collapse may result from compression of a large airway or vascular structure in the mediastinum.
  • [MeSH-minor] Anoxia / etiology. Cardiovascular Diseases / etiology. Cardiovascular Diseases / pathology. Child. Fatal Outcome. Humans. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. Pulmonary Artery / pathology. Tomography, X-Ray Computed. Ventilation-Perfusion Ratio / physiology

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618309.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


12. Shimoda K, Shide K, Kamezaki K, Okamura T, Harada N, Kinukawa N, Ohyashiki K, Niho Y, Mizoguchi H, Omine M, Ozawa K, Haradaa M: The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol; 2007 May;85(4):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anemic symptoms were present in 162 patients, and hemoglobin (Hb) concentrations were <10 g/dL in 197 patients.
  • A "good" response was defined as an Hb increase of >or=1.5 g/dL, cessation of transfusion dependence, and an Hb concentration of >10 g/dL maintained for at least 8 weeks.
  • A "minimum" response was defined as an Hb increase of >or=1.5 g/dL and transfusion independence for at least 8 weeks.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Transfusion. Chromosome Aberrations. Female. Hemoglobins / analysis. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] Stem Cells. 1997;15 Suppl 1:105-11; discussion 112 [9368330.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):1004-9 [9326204.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):78-83 [11472348.001]
  • [Cites] Leuk Res. 2005 Jul;29(7):761-9 [15927672.001]
  • [Cites] Blood. 1999 May 1;93(9):2831-8 [10216077.001]
  • [Cites] JAMA. 1962 Oct 13;182:116-9 [14031935.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2983-9 [12506018.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2534-41 [12517815.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3495-503 [12393681.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):771-5 [15953003.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1255-65 [10781623.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):194-8 [11372731.001]
  • [Cites] Blood. 1964 Mar;23:341-53 [14130445.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):308-13 [7053830.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):807-13 [15354205.001]
  • [Cites] Blut. 1978 Jul 14;37(1):19-26 [667366.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):424-31 [14752066.001]
  • [Cites] Arch Intern Med. 1982 Aug;142(8):1533-7 [7103635.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3912-8 [12920019.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2301-7 [12613516.001]
  • (PMID = 17483079.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Estrogen Antagonists; 0 / Hemoglobins; 9062ZT8Q5C / Methenolone; N29QWW3BUO / Danazol; W75590VPKQ / methenolone acetate
  •  go-up   go-down


13. Wang SS, Chou NK, Chi NH, Hsu RB, Huang SC, Chen YS, Yu HY, Tsao CI, Ko WJ, Lai MY, Chu SH: Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation. Transplant Proc; 2006 Sep;38(7):2138-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When ALT was two times greater than the upper limit of normal or serum bilirubin was higher than 3 mg/dL in HBsAg-positive patients, HBV-DNA were checked by a branched DNA assay or polymerase chain reaction.
  • Another died of diffuse B cell lymphoma at 62 months after HT.
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Female. Follow-Up Studies. Hepatitis B Surface Antigens / blood. Hepatitis C / complications. Hepatitis C / drug therapy. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome


14. Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH, Hogge DE: Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma; 2006 Jul;47(7):1245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report on a series of 375 adult (non-M3) AML patients undergoing induction chemotherapy at a single institution, leukocyte count analyzed as a continuous variable is shown to be a better predictor of induction death (ID) and overall survival (OS) than a leukocyte count of > or = 100 x 10(9)/L, a value characteristically associated with "hyperleukocytosis" (HL).
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / metabolism. Cohort Studies. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. ROC Curve. Time Factors. Treatment Outcome


15. Herro E, Dicaudo DJ, Davis MD, Weaver AL, Swanson DL: Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol; 2009 Aug;61(2):271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.
  • BACKGROUND: Having either mycosis fungoides or B-cell lymphoma may predispose a patient to the other.
  • METHODS: We retrospectively reviewed the records of patients with contemporaneous mycosis fungoides and B-cell lymphoma seen between 1990 and 2007 at Mayo Clinic, Rochester, MN, or at Mayo Clinic, Scottsdale, AZ.
  • RESULTS: In all, 23 patients had contemporaneous mycosis fungoides and B-cell malignancy.
  • The first diagnosis was mycosis fungoides in 10 patients and B-cell lymphoma in 7; in 6 patients, the diseases were diagnosed simultaneously.
  • CONCLUSION: Mycosis fungoides and B-cell lymphoma are unlikely to occur contemporaneously by chance, but no factor obviously predisposes a patient with one malignancy to development of the second.
  • [MeSH-major] Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Mycosis Fungoides / epidemiology. Mycosis Fungoides / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Academic Medical Centers. Adult. Age Distribution. Age of Onset. Aged. Biopsy, Needle. Cohort Studies. Comorbidity. Female. Humans. Immunohistochemistry. Incidence. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / pathology. Lymphoma, T-Cell, Cutaneous / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481294.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med; 2008 May 20;148(10):728-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: 54,780 HIV-infected persons in the Adult and Adolescent Spectrum of HIV Disease Project (47,832 patients) and the HIV Outpatient Study (6948 patients), who contributed 157,819 person-years of follow-up from 1992 to 2003, and 334,802,121 records from the Surveillance, Epidemiology, and End Results program of 13 geographically defined, population-based, central cancer registries.
  • RESULTS: The incidence of the following types of non-AIDS-defining cancer was significantly higher in the HIV-infected population than in the general population: anal (SRR, 42.9 [95% CI, 34.1 to 53.3]), vaginal (21.0 [CI, 11.2 to 35.9]), Hodgkin lymphoma (14.7 [CI, 11.6 to 18.2]), liver (7.7 [CI, 5.7 to 10.1]), lung (3.3 [CI, 2.8 to 3.9]), melanoma (2.6 [CI, 1.9 to 3.6]), oropharyngeal (2.6 [CI, 1.9 to 3.4]), leukemia (2.5 [CI, 1.6 to 3.8]), colorectal (2.3 [CI, 1.8 to 2.9]), and renal (1.8 [CI, 1.1 to 2.7]).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Observation. Prospective Studies. Risk Factors. Tobacco Use Disorder / complications. United States / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [SummaryForPatientsIn] Ann Intern Med. 2008 May 20;148(10):I46 [18490669.001]
  • (PMID = 18490686.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-2006-18797
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Investigator] Thompson M; Sinclair E; Cohen D; Davidson A; Rietmeijer C; Garland W; Wohl A; Morse A; Wotring L; Mokotoff E; Murrill C; Bernard MA; Amill A; de los Angeles Gomez M; Miranda S; Buskin S; Barash E; Odem S; Keiser P; Awosika-Olumo A; Wood KC; Baker RK; Palella FJ; Chmiel JS; Cheley J; Lichtenstein KA; Greenberg KS; Young B; Widick B; Stewart C; Zellner P; Yangco BG; Halkias K; Ward DJ; Fiorentino CA; Ording-Bauer L; Kelly R; Esteves J; Tedaldi EM; Christian R; Ruley F; Marzouk JB; Phelps RT; Rachel M; McCabe RE; Rachel M; Novak RM; Uy JP; Wendrow A
  •  go-up   go-down


17. Loren AW, Porter DL: Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant; 2008 Mar;41(5):483-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
  • Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with acute leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunotherapy, Adoptive / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Humans. Leukocyte Transfusion / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026156.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA11787901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


18. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA: Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr; 2007 Apr;150(4):370-5, 375.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • OBJECTIVE: To determine risk factors associated with reduced adult height in survivors of childhood acute lymphoblastic leukemia (ALL).
  • Attained adult height was determined among 2434 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 3009 siblings.
  • RESULTS: All survivor treatment exposure groups (chemotherapy alone, chemotherapy with cranial or craniospinal radiotherapy) had decreased adult height and an increased risk of adult short stature (height standard deviation score < -2) compared with siblings (P < .001).
  • CONCLUSIONS: Survivors of childhood ALL are at increased risk of adult short stature, including those treated with chemotherapy alone.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Adolesc Med. 2002 Feb;13(1):161-9, viii [11841962.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:117-24 [11992395.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Med Pediatr Oncol. 1985;13(1):14-21 [3871501.001]
  • [Cites] Am J Dis Child. 1987 May;141(5):550-2 [3578168.001]
  • [Cites] Arch Dis Child. 1987 Nov;62(11):1107-12 [3479948.001]
  • [Cites] Lancet. 1988 Feb 27;1(8583):460-2 [2893877.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):400-5 [1999710.001]
  • [Cites] Arch Dis Child. 1991 Dec;66(12):1403-7 [1776886.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Pediatr Res. 1993 Jun;33(6):577-82 [8378115.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] Arch Dis Child. 1994 Jun;70(6):472-5 [8048814.001]
  • [Cites] Acta Paediatr. 1994 Dec;83(12):1287-90 [7734872.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):167-71 [7749768.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1091-5 [8888924.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1096-101 [8888925.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):598-602 [9386666.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):351-6 [9589084.001]
  • [Cites] Eur J Pediatr. 1998 Sep;157(9):703-7 [9776525.001]
  • [Cites] Arch Dis Child. 1998 Aug;79(2):161-4 [9797600.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):139-43 [15714445.001]
  • [Cites] Nutr J. 2005;4:27 [16209706.001]
  • [Cites] Am J Dis Child. 1988 Nov;142(11):1199-202 [3177326.001]
  • [CommentIn] J Pediatr. 2007 Apr;150(4):332-4 [17382105.001]
  • (PMID = 17382112.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727-11; United States / NCI NIH HHS / CA / CA055727-11; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / T32 CA009351; United States / NCI NIH HHS / CA / CA009351-27; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCI NIH HHS / CA / T32 CA009351-27
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS21154; NLM/ PMC2766352
  •  go-up   go-down


19. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE: Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica; 2006 Apr;91(4):460-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At least 51% had received red blood cell transfusions.
  • The mean initial hemoglobin level was 9.2 g/dL (range, 4.5-15.6) and the median monoclonal immunoglobulin level 4.0 g/L (range, 0.0-47.3).
  • An abnormal kappa/lambda ratio in bone marrow was found in 90%, lymphoma in 76%, and lymphoplasmacytic lymphoma in 50%.
  • Transformation to aggressive lymphoma occurred in 3.5% during 10 years.
  • INTERPRETATION AND CONCLUSIONS: Primary CAD represents a spectrum of clonal lymphoproliferative bone marrow disorders, in most cases with morphological signs of lymphoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myeloproliferative Disorders. Norway / epidemiology. Retrospective Studies


20. Tanaka Y, Kurata M, Togami K, Fujita H, Watanabe N, Matsushita A, Maeda A, Nagai K, Sada A, Matsui T, Takahashi T: Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. Int J Hematol; 2006 Feb;83(2):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had developed intra-abdominal non-Hodgkin's lymphoma and in 1992 had received 3 courses of combination chemotherapy with doxorubicin (Adriamycin), cyclophosphamide, vincristine, methotrexate, bleomycin, and prednisolone.
  • In May 2003, anemia (hemoglobin, 7.9 g/dL) and thrombocytopenia (65 x 10(9)/L) manifested with progressive eosinophilia (21.0 x 10(9)/L) and a small number of blasts.
  • [MeSH-minor] Adult. Benzamides. Chronic Disease. Humans. Imatinib Mesylate. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Male. Molecular Sequence Data. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Sequence Analysis, DNA

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Feb 15;87(4):1416-22 [8608231.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):584-8 [15148104.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4714-6 [12595304.001]
  • [Cites] Leukemia. 2004 Apr;18(4):734-42 [14973504.001]
  • [Cites] Haematologica. 2004 Feb;89(2):236-7 [15003901.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1577-8 [12047970.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):881-4 [12127565.001]
  • [Cites] Br J Haematol. 2003 Jul;122(2):173-9 [12846884.001]
  • [Cites] MedGenMed. 2001 Sep 07;3(5):9 [11698916.001]
  • [Cites] Leuk Lymphoma. 1998 Mar;29(1-2):17-26 [9638972.001]
  • [Cites] Blood. 2003 May 1;101(9):3391-7 [12506022.001]
  • [Cites] Hematol J. 2003;4(6):410-2 [14671612.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1996 Oct;95(1):2-9 [8857931.001]
  • [Cites] Blood. 2004 Jan 15;103(2):473-8 [14504092.001]
  • [Cites] Blood. 1988 Feb;71(2):403-14 [3337904.001]
  • [Cites] Blood. 2003 Jun 15;101(12 ):4660-6 [12676775.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S79-80 [15036947.001]
  • [Cites] Medicine (Baltimore). 1975 Jan;54(1):1-27 [1090795.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):477-80 [14986065.001]
  • [Cites] N Engl J Med. 1994 Feb 24;330(8):535-8 [8302319.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):75-7 [15293573.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):51-7 [14676627.001]
  • (PMID = 16513534.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / FIP1L1-PDGFRA fusion protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


21. Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M: Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. Leuk Lymphoma; 2010 Mar;51(3):422-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
  • We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988 to 2004 with PROMECE-CYTABOM (P-C) plus involved-field radiation therapy (IF-RT).
  • Age (>60 years, p = 0.002), serum albumin (<3.5 g/dL; p = 0.015), and RT (p < 0.001) were independent predictors of OS.
  • This study confirms that patients with localized aggressive lymphoma have a high chance of cure with anthracycline containing regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Aged. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Disease-Free Survival. Epirubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prednisone / therapeutic use. Radiotherapy / methods. Retrospective Studies. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038237.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMECE-CytaBOM protocol
  •  go-up   go-down


22. He MX, Zheng JM, Wu LL, Ma DL, Zhu MH: [Morphologic study of tonsillar B-cell lymphomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):127-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic study of tonsillar B-cell lymphomas].
  • [MeSH-major] Lymphoma, B-Cell / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Tonsillectomy. Tonsillitis / pathology. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493390.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


23. Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP: Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood; 2007 Apr 1;109(7):3080-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.
  • We compared the gene expression profile of adult acute lymphoblastic leukemia (ALL) to normal hematopoietic and non-ALL samples using oligonucleotide arrays.
  • Connective tissue growth factor (CTGF) was the highest overexpressed gene in B-cell ALL compared with the other groups, and displayed heterogeneous expression, suggesting it might have prognostic relevance.
  • CTGF expression was examined by quantitative reverse transcriptase-polymerase chain reaction (ORT-PCR) on 79 adult ALL specimens.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Mol Biol Cell. 1993 Jun;4(6):637-45 [8374172.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):781-91 [15613452.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55958-68 [15496414.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2072-81 [15041728.001]
  • [Cites] J Cell Physiol. 2000 Jan;182(1):119-26 [10567923.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):756-60 [10952780.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):40-5 [11836446.001]
  • [Cites] Development. 2003 Jun;130(12):2779-91 [12736220.001]
  • [Cites] Development. 2004 May;131(9):2137-47 [15105373.001]
  • [Cites] World J Surg. 2004 Aug;28(8):818-25 [15457365.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12981-6 [9371786.001]
  • (PMID = 17170128.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / CA114762; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA32102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / DNA Primers; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139568-91-5 / Connective Tissue Growth Factor
  • [Other-IDs] NLM/ PMC1852221
  •  go-up   go-down


24. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to describe the laboratory findings and clinical course of MGUS, including association with plasma cell disorders, other malignancies, and infections, in 25 HIV-infected patients with a detectable serum monoclonal protein.
  • Laboratory studies included determination of CD4(+) T lymphocyte cell counts, HIV type 1 loads, and quantitative immunoglobulin levels; serum and urine protein immunoelectrophoresis; and determination of serum viscosity indices.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • Nine (56%) of 19 evaluable patients had a decrease of serum monoclonal protein (mean, 0.5 g/dL) while receiving HAART.
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Retrospective Studies. Sarcoma, Kaposi / complications


25. Aref S, Mossad Y, El-Khodary T, Awad M, El-Shahat E: Cyclin Dl expression in B-cell non Hodgkin lymphoma. Hematology; 2006 Oct;11(5):365-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin Dl expression in B-cell non Hodgkin lymphoma.
  • Disorders of the cell cycle regulatory machinery play a key role in the pathogenesis of cancer.
  • Over-expression of cyclin D1 protein has been reported in several solid tumors and certain lymphoid malignancies, but little is known about the effect of its expression on clinical behavior and outcome in B-cell Non-Hodgkin lymphoma (NHL).
  • In this study, we investigated the expression of cyclin Dl in group of patients with NHL and correlated the results with the clinical and laboratory data.
  • The degree of expression of cyclin Dl protein was evaluated by flow cytometry in a group of NHL patients (n = 46) and in normal control group (n = 10).
  • Cyclin Dl over expression was detected in 10 out of 46 (21.7%) patients; they were 5/5-mantle cell lymphoma (MCL) (100%) and 5/28 large B-cell lymphoma (17.8%).
  • The clinical signs (hepatomegaly, splenomegaly and B-symptoms, clinical staging) and laboratory data (hemoglobin, white cell count (WBCs), platelet count, and bone marrow infiltration) were not significantly different between NHL subgroup with cyclin Dl over expression and that with normal cyclin Dl expression.
  • Cyclin Dl over expression was evident among all cases of MCL and few cases of large B-cell lymphoma.
  • Cyclin Dl over expression might be used as adjuvant tool for diagnosis of MCL; has role in NHL biology and is bad prognostic index in NHL.
  • [MeSH-major] Cyclin D1 / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lymphatic Diseases. Male. Middle Aged. Prognosis. Up-Regulation


26. Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL: Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging; 2005 Oct;32(10):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
  • PURPOSE: The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL).
  • Four patients had received prior high-dose chemotherapy followed by autologous stem cell transplantation, and eight had received prior rituximab therapy.
  • Histopathology consisted of four mantle cell, one follicular and four diffuse large B-cell lymphomas.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Pilot Projects. Radiation Injuries / etiology. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Severity of Illness Index. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):195-7 [9652253.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1363-72 [11877767.001]
  • [Cites] Clin Immunol. 2001 Jul;100(1):40-8 [11414744.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65 [10561019.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] Nuklearmedizin. 2002 Apr;41(2):71-9 [11989301.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Nucl Med. 1990 Jan;31(1):84-9 [2295945.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s [10541376.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1276-82 [12271407.001]
  • [Cites] J Clin Oncol. 1996 Jul;14 (7):1974-81 [8683227.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S [9708567.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3246-56 [9779698.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):513-24 [14503945.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s [10541379.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):281-96 [12700944.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):766-77 [10952488.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10 ):3270-8 [9779701.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1027-38 [2666588.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):10-7 [14962257.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 1992 Nov;10 (11):1696-711 [1403053.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 15937686.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals
  •  go-up   go-down


27. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ: Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol; 2007 Oct 10;25(29):4648-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
  • PURPOSE: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly.
  • Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, beta2-microglobulin at least 2 mg/L, albumin less than 3.5 g/dL, and creatinine at least 1.6 mg/dL were each found to independently predict shorter survival and formed the basis of a scoring system.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphocyte Count
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD38 / biosynthesis. Diagnosis, Differential. Disease-Free Survival. Humans. Middle Aged. Prognosis. Texas. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


28. Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM: High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant; 2005 Jan;11(1):13-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
  • Over a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin lymphoma patients were treated at our center with high-dose chemotherapy and autologous transplantation.
  • Thirty-two patients had indolent (low-grade), 42 had aggressive (intermediate-grade), and 27 had very aggressive (high-grade) non-Hodgkin lymphoma.
  • Most patients (n = 93) received mobilized peripheral blood stem cells (median CD34 + cell dose, 6.7 x 10 6 /kg).
  • Four patients (4%) died within 30 days of stem cell infusion (1 pulmonary embolism, 2 septicemias with multiorgan failure, and 1 progressive lymphoma).
  • BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / mortality. Salvage Therapy / methods. Salvage Therapy / mortality. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625540.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


29. Anghelescu DL, Faughnan LG, Baker JN, Yang J, Kane JR: Use of epidural and peripheral nerve blocks at the end of life in children and young adults with cancer: the collaboration between a pain service and a palliative care service. Paediatr Anaesth; 2010 Dec;20(12):1070-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ten patients (4.4-21.3 years of age), nine with solid tumors, one with lymphoma, had 14 devices (11 epidural, 3 peripheral nerve catheters) for a range of 3-81 days.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21199115.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / 5P30CA021765-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Other-IDs] NLM/ NIHMS676607; NLM/ PMC4403725
  •  go-up   go-down


30. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E, Integruppo Italiano Linfomi: Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood; 2006 Jun 15;107(12):4643-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic marginal zone lymphoma: a prognostic model for clinical use.
  • The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients.
  • In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100,000/microL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006).
  • Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL.
  • This latter group accounted for 54% of all lymphoma-related deaths.
  • [MeSH-major] Lymphoma, B-Cell / mortality. Models, Theoretical. Splenic Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Albumins / analysis. Disease-Free Survival. Hemoglobins / analysis. Humans. Hydro-Lyases / blood. Longitudinal Studies. Male. Middle Aged. Multivariate Analysis. Platelet Count. Predictive Value of Tests. Prognosis. Risk Factors. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493005.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Hemoglobins; EC 4.2.1.- / Hydro-Lyases; EC 4.2.1.54 / lactate dehydratase
  •  go-up   go-down


31. Koharazawa H, Kanamori H, Sakai R, Hashimoto C, Takemura S, Hattori M, Taguchi J, Fujimaki K, Tomita N, Fujita H, Fujisawa S, Harano H, Ogawa K, Motomura S, Maruta A, Ishigatsubo Y: Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Nov;49(11):2133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
  • By univariate analysis, we identified seven adverse factors for DFS which included the L2 subtype by French-American-British classification, hepatosplenomegaly, a white blood cell count of more than 30 x 10(9)/L, a blast cell count of more than 10 x 10(9)/L in the peripheral blood, hemoglobin concentration greater than 10 g/dL, a serum lactate dehydrogenase value greater than twice the upper limit of normal and the presence of the Philadelphia chromosome (Ph).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Asparaginase / administration & dosage. Female. Humans. Longitudinal Studies. Male. Middle Aged. Philadelphia Chromosome. Prednisolone / administration & dosage. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021056.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


32. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Li L, Luo XL: [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):594-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
  • OBJECTIVE: To study the differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • RESULTS: Histologically, a few atypical large cells scattered in a background of small lymphocytes with or without histiocytes were a common finding in both NLPHL and TCRBCL.
  • Of NLPHL, nodular pathern predominated in 11 cases, diffuse patterns without nodules in 3 cases and one case showed nodular and diffuse pattern intermixed with a increased number of large cells.
  • 14 cases of TCRBCL showed diffuse pattern.
  • One case showed a combination of nodules of NLPHL, diffuse areas of TCRBCL and a sheet of large cells of diffuse large B-cell lymphoma (DLBCL) within the same lymph node biopsy specimen.
  • Immunophenotypically, the large cells showed and CD20, CD79a, bcl-6 and EMA positive, and CD15, CD30, CD3, CD45RO and LMP-1 negative.
  • [MeSH-major] Hodgkin Disease / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD57 / metabolism. Child. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunophenotyping. Male. Middle Aged. Poly(A)-Binding Proteins / metabolism. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243292.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD57; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


33. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA: Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer; 2006 Oct 15;107(8):1909-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, or multiple myeloma and baseline hemoglobin of 10 to 12 g/dL who were scheduled for > or = 4 months of myelosuppressive chemotherapy were randomized to receive < or = 16 weeks of epoetin alfa at a dose of 40,000 U once weekly immediately (early) or to wait and only receive epoetin alfa if hemoglobin decreased to < 9 g/dL (late).
  • Those patients with a hemoglobin level > 12 g/dL after 3 chemotherapy cycles were not randomized.
  • RESULTS: In all, 269 patients with a hemoglobin level < or = 12 g/dL were randomized.
  • The mean hemoglobin increased 1.2 g/dL (95% CI, 0.98-1.46) in early patients but decreased 0.2 g/dL (95% CI, -0.32-0.12) in late patients (P < .0001).
  • CONCLUSIONS: Treating mild anemia immediately with epoetin alfa during chemotherapy for hematologic malignancy significantly improved QOL, productivity, and hemoglobin compared with delaying treatment until the hemoglobin level decreases to < 9.0 g/dL.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epoetin Alfa. Fatigue / epidemiology. Female. Hemoglobins / analysis. Humans. Male. Middle Aged. Recombinant Proteins. Work Capacity Evaluation

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16977654.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa
  •  go-up   go-down


34. Anghelescu DL, Burgoyne LL, Liu T, Li CS, Pui CH, Hudson MM, Furman WL, Sandlund JT: Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses. Paediatr Anaesth; 2007 Nov;17(11):1090-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses.
  • BACKGROUND: The presence of a mediastinal mass in a child poses significant anesthesia-related risks including death.
  • To optimize outcome clinicians must be able to predict which patients are at highest risk of anesthetic complications.
  • METHODS: We conducted a retrospective review of 118 pediatric patients who presented with mediastinal masses.
  • We investigated their medical records for clinical symptoms and signs at presentation and reviewed their chest radiographs, computed tomography scans, and echocardiograms and electrocardiograms when available.
  • We then conducted analyses to identify clinical and diagnostic imaging features associated with anesthesia-related complications.
  • RESULTS: Eleven of 117 [9.4%, 95% confidence interval (CI) 4.1-14.7%] patients experienced an anesthesia-related complication.
  • Four preoperative features were significantly associated with anesthetic complications: orthopnea (P = 0.033, odds ratio (OR) 5.31, 95% CI, 1.15-24.56), upper body edema (P = 0.035, OR 8.00, 95% CI, 1.16-55.07), great vessel compression (P = 0.037, OR 5.41, 95% CI, 1.11-26.49), and main-stem bronchus compression (P = 0.044, OR 5.11, 95% CI, 1.05-24.92).
  • The presence of pleural effusion (P = 0.060, OR 4.53, 95% CI, 0.94-21.96) or tracheal compression (P = 0.061, OR 5.09, 95% CI, 0.93-27.81) also appeared to be risk factors.
  • Although the rate of anesthesia-related complications detected in our cohort was comparable with that found in earlier studies, the events were less severe.
  • CONCLUSIONS: Patients who present with orthopnea, upper body edema, great vessel compression and main stem bronchus compression are at risk of anesthesia-related complications.
  • The low severity of complications in our series may reflect a combination of factors: use of the least invasive method such as interventional radiology to obtain tissue for diagnosis, completion of a thorough preoperative assessment and minimal anesthesia intervention.


35. Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG: A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol; 2008 Dec;63(1):65-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
  • PURPOSE: This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies.
  • EXPERIMENTAL DESIGN: This was a phase I study to determine the maximal-tolerated dose of escalating doses of PI-88 administered subcutaneously for 4 days per week, along with docetaxel 30 mg/m(2) given on days 1, 8, 15 of a 28-day schedule.
  • RESULTS: Sixteen patients received a total of 42 courses of therapy.
  • No dose-limiting toxicities were observed despite escalation to the highest planned dose level of PI-88 (250 mg/day).
  • Frequent minor toxicities included fatigue (38%), dysgeusia (28.5%), thrombocytopenia (12%), diarrhea (14%), nausea (12%), and emesis (10%) in the 42 courses.
  • No significant bleeding complications were observed.
  • One patient developed a positive anti-heparin antibody test/serotonin releasing assay with positive anti-platelet factor 4/PI-88 antibodies and grade 1 thrombocytopenia in cycle 5, and was withdrawn from the study without any sequelae.
  • PI-88 plasma concentrations (mirrored by APTT) and urinary elimination were linear and dose-proportional.
  • Docetaxel did not alter the pharmacokinetic (PK) profile of PI-88, nor did PI-88 affect docetaxel PK.
  • No significant relationship was determined between plasma or urine FGF-2, or plasma VEGF levels and PI-88 dose/response.
  • Although no objective responses were observed; 9 of the 15 evaluable patients had stable disease for greater than two cycles of therapy.
  • CONCLUSION: PI-88 administered at 250 mg/day for 4 days each week for 3 weeks with docetaxel 30 mg/m(2) on days 1, 8 and 15, every 28 days, was determined to be the recommended dose level for phase II evaluation.
  • This combination was well tolerated without severe toxicities or PK interactions.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cell. 1991 Feb 22;64(4):841-8 [1847668.001]
  • [Cites] Trends Cell Biol. 2001 Feb;11(2):75-82 [11166215.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1299-305 [11350898.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4655-9 [11406531.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3500-5 [11481356.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2158-63 [11596033.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1062-73 [11676857.001]
  • [Cites] Ann Oncol. 2002 May;13(5):770-6 [12075747.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1817-23 [12204662.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] J Exp Med. 2002 Dec 2;196(11):1497-506 [12461084.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):233-8 [12634618.001]
  • [Cites] Cancer Lett. 2003 Apr 10;193(1):83-9 [12691827.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):159-66 [12759775.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7737-49 [14586400.001]
  • [Cites] Thromb Haemost. 1992 Jul 6;68(1):95-6 [1514184.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):431-9 [7734342.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Ann Oncol. 1996 Jul;7(5):491-6 [8839904.001]
  • [Cites] FASEB J. 1997 Jan;11(1):51-9 [9034166.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):187-96 [9440742.001]
  • [Cites] Semin Hematol. 1998 Oct;35(4 Suppl 5):3-8; discussion 35-6 [9855178.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3433-41 [10416607.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:60-3 [10436787.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):624-31 [15581974.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Lung Cancer. 2005 Dec;50 Suppl 2:S25-32 [16557671.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3124-9 [16707611.001]
  • [Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):134-9 [16527339.001]
  • [Cites] Curr Med Chem. 2006;13(18):2101-11 [16918340.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5471-80 [17000682.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6100-5 [17062686.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2363-73 [17121850.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):433-45 [17428164.001]
  • [Cites] Ann Med. 2006;38(8):545-51 [17438669.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):454-5 [17454583.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5 Suppl):S19-23 [17457224.001]
  • [Cites] Clin Trials. 2007;4(3):235-44 [17715248.001]
  • [Cites] Lung Cancer. 2005 Dec;50 Suppl 2:S3-8 [16557668.001]
  • [Cites] Clin Breast Cancer. 2003 Oct;4(4):292-4 [14651775.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1976-83 [15041715.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):556-63 [15260846.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30 [15316057.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1358-65 [15319242.001]
  • [Cites] Oncologist. 2004;9(5):538-45 [15477638.001]
  • [Cites] N Z Med J. 1980 Dec 10;92(673):425-6 [6937780.001]
  • [Cites] Blood. 1986 Jan;67(1):27-30 [3940551.001]
  • [Cites] Br J Clin Pharmacol. 1989 Sep;28(3):275-80 [2789921.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:20-7 [10804087.001]
  • (PMID = 18320191.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106349-05; United States / NCI NIH HHS / CA / K24 CA106349; United States / NCI NIH HHS / CA / K24 CA106349-05
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Neoplasm Proteins; 0 / Oligosaccharides; 0 / Taxoids; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / phosphomannopentaose sulfate; 103107-01-3 / Fibroblast Growth Factor 2; 15H5577CQD / docetaxel; 37270-94-3 / Platelet Factor 4; 9005-49-6 / Heparin; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  • [Other-IDs] NLM/ NIHMS169569; NLM/ PMC2813677
  •  go-up   go-down


36. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R, International Peripheral T-Cell Lymphoma Project: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood; 2009 Apr 23;113(17):3931-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
  • Among 1153 new adult cases of peripheral/T-cell lymphoma from 1990-2002 at 22 centers in 13 countries, 136 cases (11.8%) of extranodal natural killer (NK)/T-cell lymphoma were identified (nasal 68%, extranasal 26%, aggressive/unclassifiable 6%).
  • Among nasal cases, both the International Prognostic Index (P = .006) and Korean NK/T-cell Prognostic Index (P < .001) were prognostic.
  • In addition, Ki67 proliferation greater than 50%, transformed tumor cells greater than 40%, elevated C-reactive protein level (CRP), anemia (< 11 g/dL) and thrombocytopenia (< 150 x 10(9)/L) predicts poorer OS for nasal disease.
  • We conclude that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genotype. Humans. Male. Middle Aged. Phenotype. Prognosis. Societies, Medical. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Jun 11;113(24):6260-1; author reply 6261-2 [19520819.001]
  • (PMID = 19029440.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Ferreira JA; Delgado BM; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; Lister A; Norton A; MacLennan KA; Zinzani PL; Pileri S; Federico M; Bellei M; Coiffier B; Berger F
  •  go-up   go-down


37. Han X, O'Connor JC, Donner EM, Nabb DL, Mingoia RT, Snajdr SI, Clarke JJ, Kaplan AM: Non-coplanar 2,2',3,3',4,4',5,5',6,6'-decachlorobiphenyl (PCB 209) did not induce cytochrome P450 enzyme activities in primary cultured rat hepatocytes, was not genotoxic, and did not exhibit endocrine-modulating activities. Toxicology; 2009 Jan 31;255(3):177-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCB 209 (dose from 25 to 150 microg/mL) was also negative for forward mutations at the thymidine kinase (TK+/-) locus of L5178Y mouse lymphoma cells.
  • The Ames and the mouse lymphoma assays were both conducted in the absence and presence of rat liver S9 fraction.
  • PCB 209 did not induce estrogenic effects when administered by gavage to ovariectomized adult female rats at 500 and 1000 mg/kg for 4 days, nor did it produce alterations consistent with endocrine-modulating activity in adult intact male rats when administered by gavage at 500 and 1000 mg/kg for 15 consecutive days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022331.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Endocrine Disruptors; 9035-51-2 / Cytochrome P-450 Enzyme System; DFC2HB4I0K / Polychlorinated Biphenyls; N8AL7T0ATT / decachlorobiphenyl
  •  go-up   go-down


38. Manabe N, Tanaka S, Fukumoto A, Nakao M, Kamino D, Chayama K: Double-balloon enteroscopy in patients with GI bleeding of obscure origin. Gastrointest Endosc; 2006 Jul;64(1):135-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Criteria for inclusion in the study were documented iron deficiency anemia (hemoglobin level <10 g/dL or a decrease of >2 g/dL over > or =2 months); upper endoscopy not revealing a site/cause of blood loss; and similarly uninformative lower endoscopy including examination of the terminal ileum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Gastrointestinal Neoplasms / diagnosis. Hemangioma / diagnosis. Humans. Jejunal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813826.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA: Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol; 2009 Jul 20;27(21):3518-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-two patients successfully underwent optional stem-cell transplantation.
  • [MeSH-major] Boronic Acids / therapeutic use. Multiple Myeloma / drug therapy. Neoplasm Recurrence, Local / complications. Peripheral Nervous System Diseases / therapy. Pyrazines / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Bortezomib. Drug Resistance, Neoplasm. Drug Synergism. Female. Humans. Male. Middle Aged. Polyneuropathies / etiology. Protease Inhibitors. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4452-8 [17785704.001]
  • [Cites] Oncologist. 2007 Aug;12(8):978-90 [17766658.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] Br J Haematol. 2008 May;141(4):512-6 [18371113.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2171-7 [18362366.001]
  • [Cites] Cancer Nurs. 2008 May-Jun;31(3):239-49 [18453881.001]
  • [Cites] Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):29-36 [18490255.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):895-903 [19170677.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Oct;7(9):908-42 [19878637.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):1910-21 [17917960.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):16-9 [12506164.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8 [14675309.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):875-82 [15244383.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):485-90 [15286691.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Arch Neurol. 1971 Nov;25(5):404-14 [4329368.001]
  • [Cites] Neurology. 1981 Jan;31(1):24-31 [6256682.001]
  • [Cites] Neurology. 1999 Nov 10;53(8):1634-40 [10563605.001]
  • [Cites] Neurology. 1999 Nov 10;53(8):1641-7 [10563606.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2):215-7 [11807432.001]
  • [Cites] Blood. 1992 Aug 15;80(4):887-90 [1498331.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Arch Neurol. 1963 Nov;9:534-44 [14057685.001]
  • [Cites] Neurology. 2005 Jan 25;64(2):199-207 [15668414.001]
  • [Cites] Leuk Res. 2005 May;29(5):587-90 [15755512.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Best Pract Res Clin Haematol. 2005;18(4):673-88 [16026744.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):431-6 [16365178.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1292-8 [16174762.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16687729.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4507-14 [16940275.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2165-72 [16772605.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1498-505 [17043025.001]
  • [Cites] JAMA. 2006 Dec 6;296(21):2558-60 [17148721.001]
  • [Cites] Leukemia. 2007 Jan;21(1):164-8 [17096015.001]
  • [Cites] Leukemia. 2007 Jan;21(1):151-7 [17096017.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):149-62 [17335684.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3177-88 [17185464.001]
  • [Cites] Oncologist. 2007 Jun;12(6):664-89 [17602058.001]
  • [Cites] Neurology. 2007 Aug 7;69(6):573-81 [17679676.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):115-30 [17692804.001]
  • [CommentIn] Nat Rev Clin Oncol. 2009 Dec;6(12):683-5 [19942924.001]
  • (PMID = 19528374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30 EY012196; United States / NINDS NIH HHS / NS / R01 NS042866; United States / NEI NIH HHS / EY / P30 EY 12196; United States / NINDS NIH HHS / NS / R01NS42866
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2717758
  •  go-up   go-down


40. Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M: Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol; 2009 Jul;90(1):99-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 38-year-old man, diagnosed as having multicentric Castleman's disease (plasma cell type) in 1995, had been treated with melphalan and prednisolone or prednisolone alone, but there was no remarkable response.
  • Laboratory data showed high serum IgG (10050 mg/dl), interleukin-6 (37.9 ng/ml), and vascular endothelial growth factor (VEGF 1920 pg/ml) levels.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Humans. Immunoglobulin G / blood. Interleukin-6 / blood. Male. Vascular Endothelial Growth Factor A / blood


41. Glasheen JJ, Sorensen MD: Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation. Leuk Lymphoma; 2005 Feb;46(2):281-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation.
  • We present what appears to be the first reported case of lactic acidosis and hypoglycemia in an adult patient with Burkitt's lymphoma.
  • Lactic acidosis and hypoglycemia are rare complications of non-Hodgkin's lymphoma (NHL) with only 26 and 8 previous reports, respectively.
  • Two prior cases of Burkitt's lymphoma-induced lactic acidosis have been reported (one child, one adult), both in the absence of hypoglycemia.
  • Thoracentesis and bone marrow studies revealed Burkitt's lymphoma.
  • On the second day of his hospitalization he developed severe lactic acidosis (pH 7.29, lactate 15.8 mmol/L) and hypoglycemia (27 - 60 mg/dl) resistant to glucose infusions.
  • [MeSH-major] Acidosis, Lactic / etiology. Burkitt Lymphoma / complications. Hypoglycemia / etiology


42. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, Friedman DL: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant; 2010 Dec;16(12):1674-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the prevalence of and risk factors for adverse cardiometabolic traits in a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell transplantation (HCT) in this cross-sectional pilot study.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1521-5 [15585763.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Cardiovasc Res. 2007 Apr 1;74(1):11-8 [17140553.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3463-71 [17664354.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):160-4 [18206681.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):177-84 [18206686.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):185-90 [18206687.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):797-804 [18195686.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Jun;21(2):129-38 [18503981.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):11-26 [18430191.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Nov;69(5):819-27 [18429947.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5537-43 [18809605.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):49-54 [18724397.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3698-704 [19564534.001]
  • [Cites] PLoS Genet. 2009 Dec;5(12):e1000768 [20011104.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81 [20056636.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24 [19961945.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):993-7 [11041401.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2184-91 [11481415.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90 [14767193.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):439-44 [15480363.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Can J Public Health. 1986 Sep-Oct;77(5):359-62 [3791117.001]
  • [Cites] Am J Epidemiol. 1996 Jun 15;143(12):1219-28 [8651220.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1650-6 [9614255.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1376-83 [15548978.001]
  • (PMID = 20685399.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024975-01; United States / NCRR NIH HHS / RR / UL1 RR025014-01; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; None / None / / UL1 RR025014-01; United States / NCRR NIH HHS / RR / UL1RR025014; United States / NCRR NIH HHS / RR / UL1RR024975; United States / NCRR NIH HHS / RR / UL1 RR025014; United States / NCRR NIH HHS / RR / UL1 RR024975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS211258; NLM/ PMC2975816
  •  go-up   go-down


43. Webster AC, Supramaniam R, O'Connell DL, Chapman JR, Craig JC: Validity of registry data: agreement between cancer records in an end-stage kidney disease registry (voluntary reporting) and a cancer register (statutory reporting). Nephrology (Carlton); 2010 Jun;15(4):491-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Agreement was poorest for melanoma (kappa = 0.61) and myeloma (kappa = 0.47) and highest for lymphoma (kappa = 0.80), leukaemia (kappa = 0.86) and breast cancer (kappa = 0.85).
  • [MeSH-minor] Adult. Aged. Australia / epidemiology. Data Collection. Epidemiologic Research Design. Female. Humans. Incidence. Kidney Transplantation / statistics & numerical data. Male. Middle Aged. Models, Statistical. New Zealand / epidemiology. Renal Dialysis / statistics & numerical data. Reproducibility of Results. Young Adult


44. Dogan E, Erkoc R, Sayarlioglu H, Alici S, Dilek I, Alici O: Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report. Adv Ther; 2005 Sep-Oct;22(5):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report.
  • This is a case report of LA due to leukemic transformation that occurred in a patient with non-Hodgkin's lymphoma (NHL).
  • Venous blood gas analysis revealed metabolic acidosis (pH 7.05; HCO3 6 mEq/L; BE 22 mmol/L; anion gap 28 mEq/L); the patient had an elevated plasma lactate concentration (12 mmol/L) and low glucose concentration (38 mg/dL).
  • [MeSH-major] Acidosis, Lactic / etiology. Leukemia, Promyelocytic, Acute / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418152.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N: Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol; 2009 Mar;39(3):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and twenty-two patients with lung cancer or malignant lymphoma undergoing chemotherapy were randomized to the EPO 36 000 IU group or the placebo group.
  • Hematological response and red blood cell (RBC) transfusion requirement were assessed.
  • RESULTS: Mean change in hemoglobin level with EPO increased significantly over placebo (1.4 +/- 1.9 g/dl versus -0.8 +/- 1.5 g/dl; P < 0.001).
  • The proportion of patients with change in hemoglobin level > or =2.0 g/dl was higher for EPO than those for placebo (P < 0.001).
  • After 4 weeks of administration, the proportion of RBC transfusion or hemoglobin level <8.0 g/dl was significantly lower for EPO than those for placebo (P = 0.046).
  • Thrombovascular events and pure red cell aplasia related to EPO were not observed.
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Double-Blind Method. Drug Administration Schedule. Female. Hemoglobins / metabolism. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Prospective Studies. Quality of Life. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164318.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hematinics; 0 / Hemoglobins; 0 / Recombinant Proteins; 0 / epoetin beta; 11096-26-7 / Erythropoietin
  •  go-up   go-down


46. Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, Henning AK, Holman J Jr, First MR, CRAF Study Group: Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation; 2008 May 15;85(9):1261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At 60 months, the median change from baseline in serum creatinine was -0.2 mg/dL in the tacrolimus group and 0.3 mg/dL in the cyclosporine group (P=0.003).
  • The incidence of new-onset diabetes, hyperglycemia, hypertension, lymphoma, and malignancies was generally low and comparable between groups.
  • Fewer patients in the tacrolimus group than in the cyclosporine group developed new cardiac conditions (11% vs. 28%, P=0.004), had low-density lipoprotein (LDL) cholesterol values more than 130 mg/dL (29% vs. 57%, P=0.002), or developed hyperlipidemia (24% vs. 67%, P=0.046) during the 60-month follow-up period.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Kidney Function Tests. Male. Middle Aged. Patient Selection. Survival Analysis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Nephrol. 2008 Nov;4(11):598-9 [18797447.001]
  • (PMID = 18475181.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  • [Investigator] Waid T; Alfrey E; Mulloy LC; Shihab FS; Conti D; Freeman R; deMattos AM; Jensik SC; Jordan S; Francos GC; Van Buren D; Chan L; Steiner RW; Basadonna G; Brinker K; Steinberg S; Matas AJ; King AL; Kasiske BL; Cohen DJ; Surer D; Inokuchi S; Pirsch JD; Bromberg JS; Weir MR; Greenstein SM; Tomlanovich SJ; Mendez R; Kahana L; Henning AK; First MR; Fitzsimmons WE; Salm K; Tolzman D
  •  go-up   go-down


47. Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant; 2005 Dec;36(11):955-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
  • Although follicular lymphoma (FL) is generally responsive to conventional-dose chemotherapy, improved survival in patients with this disease has been difficult to demonstrate.
  • High-dose chemo/radiotherapy followed by autologous stem-cell transplantation (ASCT) can improve response rates, although its effects on survival remain controversial.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / therapy. Lymphoma, Non-Hodgkin / therapy. Survivors
  • [MeSH-minor] Adult. Age Factors. Aged. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Autologous


48. Taylor AJ, Croft AP, Palace AM, Winter DL, Reulen RC, Stiller CA, Stevens MC, Hawkins MM: Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer; 2009 Nov 15;125(10):2400-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk of thyroid cancer was highest after Hodgkin's disease: RR 3.3 (1.1-10.1) and Non Hodgkin's Lymphoma: RR 3.4 (1.1-10.7) relative to leukaemia (RR 1.0) (p < 0.001).
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / etiology. Adolescent. Adult. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / etiology. Child. Cohort Studies. Dose-Response Relationship, Radiation. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Prognosis. Risk Assessment. Risk Factors. Survival Rate. Survivors. Young Adult


49. Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG: Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol; 2006 Aug;45(2):197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study.
  • Increased risk was detected for Burkitt's lymphoma and HBV (SIR 12.9, 95% CI 5.4-30.9) and immunoproliferative malignancies following HCV (SIR 5.6, 95% CI 1.8-17.5).
  • [MeSH-minor] Adult. Female. Humans. Incidence. Male. New South Wales / epidemiology. Retrospective Studies. Risk Factors


50. Westhoff TH, Loddenkemper C, Hörl MP, Schmidt S, Anagnostopoulos I, Hummel M, Zidek W, van der Giet M: Dermatopathic lymphadenopathy: a differential diagnosis of enlarged lymph nodes in uremic pruritus. Clin Nephrol; 2006 Dec;66(6):472-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He turned out to be uremic due to focal segmental glomerulosclerosis (creatinine 4.5 mg/dl, MDRD creatinine clearance 12 ml/min).
  • T cell lymphoma was excluded by PCR for T cell receptor-gamma rearrangements and subsequent GeneScan analysis.
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Lymphoma, T-Cell, Cutaneous / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Itching.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17176922.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Kadan-Lottick NS, Kawashima T, Tomlinson G, Friedman DL, Yasui Y, Mertens AC, Robison LL, Strong LC: The risk of cancer in twins: a report from the childhood cancer survivor study. Pediatr Blood Cancer; 2006 Apr;46(4):476-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current report, a large cohort of childhood cancer survivors was used to:.
  • RESULTS: Seven monozygotic twin pairs were concordant for cancer (six for leukemia, one for non-Hodgkin lymphoma), yielding probandwise concordance rates of 9.5%, 20.7%, and 20.0% for all cancer, leukemia, and non-Hodgkin lymphoma (NHL), respectively.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Ontario / epidemiology. Risk Factors. Siblings. Survival Analysis. United States / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Apr;46(4):412-3 [16155936.001]
  • (PMID = 16078231.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K12RR17594; United States / NCI NIH HHS / CA / P01 CA34936; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  •  go-up   go-down


52. Ma MC, Wang MC, Pei SN, Kuo CY: Hepatosplenic fungal infection in adult patients with acute leukemia. Chang Gung Med J; 2008 Jan-Feb;31(1):74-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic fungal infection in adult patients with acute leukemia.
  • BACKGROUND: Hepatosplenic fungal infection is an important infectious complication in adult patients with acute leukemia.
  • METHODS: From 2001 to 2004, 163 adult patients were diagnosed with acute leukemia at our center: 41 patients had acute lymphoblastic leukemia (ALL) and 122 patients had acute myeloid leukemia (AML).
  • Duration of agranulocytosis (absolute neutrophil count < 500/dl) was 10 to 36 days, with a median of 20 days.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Liver Diseases / etiology. Mycoses / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Antifungal Agents / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies


53. Nakagawa M, Kimura S, Fujimoto K, Atumi H, Imura J, Chikazawa Y, Imamura H, Okuyama H, Yamaya H, Fukushima T, Nakagawa A, Asaka M, Yokoyama H: A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. Ther Apher Dial; 2008 Dec;12(6):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
  • PE remarkably reduced both serum triglyceride and total cholesterol levels from 5430 mg/dL to 403 mg/dL and from 623 mg/dL to 204 mg/dL, respectively.
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Asparaginase / adverse effects. Asparaginase / therapeutic use. Cholesterol / blood. Humans. Lipoprotein Lipase / deficiency. Lipoprotein Lipase / genetics. Lipoprotein Lipase / metabolism. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction. Severity of Illness Index. Triglycerides / blood. Young Adult

  • MedlinePlus Health Information. consumer health - Triglycerides.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140851.001).
  • [ISSN] 1744-9987
  • [Journal-full-title] Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • [ISO-abbreviation] Ther Apher Dial
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; EC 3.1.1.34 / Lipoprotein Lipase; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


54. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A, Australasian Leukaemia and Lymphoma Group: Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood; 2008 Nov 15;112(10):3965-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Dose-Response Relationship, Drug. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18768781.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


55. Lee SH, Kim HJ, Mun JS, Oh HC, Lee HW, Choi CH, Kim JW, Do JH, Kim JG, Chang SK, Kim MK: A case of primary hepatic Burkitt's lymphoma. Korean J Gastroenterol; 2008 Apr;51(4):259-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary hepatic Burkitt's lymphoma.
  • Burkitt's lymphoma is a rare disease that belongs to the aggressive non-Hodgkin's lymphoma.
  • Herein, we report a case of primary hepatic Burkitt's lymphoma.
  • Laboratory finding showed mild anemia (hemoglobin, 12.4 g/dL), mild elevated transaminase (ALT, 52 IU/L), elevated lactate dehydrogenase (LDH, 437 IU/L), and alkaline phosphatase (ALP, 129 IU/L).
  • Abdominal-Pelvis CT scan and abdominal MRI finding were compatible with malignant lymphoma.
  • Liver biopsy examination confirmed Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Diagnosis, Differential. Humans. Male. Methotrexate / therapeutic use. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516006.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Lee SW, Park MC, Kim H, Park YB, Lee SK: Dermatopathic lymphadenopathy in a patient with adult onset Still's disease. Clin Exp Rheumatol; 2007 Mar-Apr;25(2):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatopathic lymphadenopathy in a patient with adult onset Still's disease.
  • Adult onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown cause characterized by high fever accompanied by systemic manifestations.
  • Dermatopathic lymphadenopathy (DL) is characterized by a localized paracortical proliferation of histiocytes and deposition of melanin in the lymph nodes.
  • DL is not only a reactive hyperplasia of the lymph nodes, but has also been reported to be associated with hematological malignancies such as cutaneous T cell lymphoma (CTCL) and Hodgkin's lymphoma.
  • It is therefore important to evaluate CTCL or Hodgkin's lymphoma in a patient with DL, in order to both rule out hematological malignancy and diagnose AOSD.
  • In this report, we first describe a 37-year-old patient with AOSD whose biopsy of lymph node was proved to be DL.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Diseases / etiology. Still's Disease, Adult-Onset / complications
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Hodgkin Disease / diagnosis. Humans. Lymphoma, T-Cell, Cutaneous / diagnosis. Melanins / metabolism

  • Genetic Alliance. consumer health - Still's disease adult onset.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543161.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


57. Stine KC, Saylors RL, Saccente CS, Becton DL: Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost; 2007 Apr;13(2):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-molecular-weight heparin such as enoxaparin has become widely used in adult patients with thrombosis.
  • Diagnosis included B-precursor acute lymphoblastic leukemia (ALL) (n=three), T-ALL, Hodgkin's disease, anaplastic large cell lymphoma, and rhabdomyosarcoma (n=one each).

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456625.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin
  •  go-up   go-down


58. Yu XQ, Chen WH, O'Connell DL: Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer; 2010 May 24;10:231
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.
  • BACKGROUND: We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2344-50 [17107908.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):566-77 [12226004.001]
  • [Cites] Drugs. 2003;63(8):803-43 [12662126.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Stat Med. 2004 Jan 15;23(1):51-64 [14695639.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):138-43 [14744745.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):611-8 [15280640.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):2004-10 [8909323.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270-86 [15417650.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):73-81 [16170828.001]
  • [Cites] Am J Clin Oncol. 2007 Apr;30(2):163-71 [17414466.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Annu Rev Med. 2008;59:237-50 [18186705.001]
  • [Cites] Arch Intern Med. 2008 Mar 10;168(5):469-76 [18332290.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S107-9 [18813239.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):630-8 [16614102.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):228-9 [16682983.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):894-900 [16550595.001]
  • [Cites] J Intern Med. 2006 Aug;260(2):103-17 [16882274.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2417-22 [16964611.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2786-93 [16930993.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • (PMID = 20497580.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / 550002
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2886045
  •  go-up   go-down


59. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M, Keating A: Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leuk Lymphoma; 2005 Apr;46(4):525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Predictive Value of Tests. Remission Induction. Retrospective Studies. Risk Factors. Transplantation, Autologous. Treatment Failure. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019480.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


60. Savaşan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y: CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma; 2006 Oct;47(10):2076-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Cell Membrane / metabolism. Child. Child, Preschool. Cytarabine / pharmacology. Daunorubicin / pharmacology. Down Syndrome / complications. Humans. Immunophenotyping. Infant. Infant, Newborn. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2004-5 [17071466.001]
  • (PMID = 17071479.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / U10 CA 30969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD36; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


61. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A, German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol; 2008 Jan 20;26(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
  • PURPOSE: Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is rare and differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • In LPHL patients, negative prognostic factors were advanced stage (P = .0092), Hb less than 10.5 g/dL (P = .0171), and lymphopenia (P = .010) for FFTF.
  • Age >or= 45 years (P = .0125), advanced stage (P = .0153), and Hb less than 10.5 g/dL (P = .0014) were negative prognostic factors for OS.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):368-9 [18542117.001]
  • (PMID = 18086799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Suh SY, Ahn HY: A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer; 2007 Jun;15(6):613-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival time of the elevated CRP group (> or =2.2 mg/dl) was found to be significantly shorter than the lower CRP group in univariate analysis (hazard rate = 3.221, P = 0.001).
  • In multivariate analysis, elevated CRP level (> or =2.2 mg/dl) was selected as one of the unfavorable indicators regarding survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Aug;182(2):197-201 [11574097.001]
  • [Cites] Palliat Med. 1993;7(3):199-204 [8261188.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):84-91 [11857390.001]
  • [Cites] J Pain Symptom Manage. 1995 Oct;10(7):548-55 [8537697.001]
  • [Cites] Arthritis Rheum. 2005 Feb 15;53(1):33-8 [15696567.001]
  • [Cites] J Pain Symptom Manage. 1999 Apr;17(4):231-9 [10203875.001]
  • [Cites] Am J Surg. 1995 Oct;170(4):319-22 [7573721.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):310-5 [14993027.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1090-8 [15329920.001]
  • [Cites] Leuk Lymphoma. 1998 Oct;31(3-4):351-7 [9869199.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):391-7 [12551861.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2004 Aug;29(4):307-13 [15270813.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):970-6 [15309885.001]
  • [Cites] Cancer. 2005 May 1;103(9):1856-64 [15779015.001]
  • [Cites] Nutr Cancer. 1998;31(2):101-5 [9770720.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):255-60 [11167877.001]
  • [Cites] J Pain Symptom Manage. 2002 Oct;24(4):424-8 [12505211.001]
  • [Cites] Am J Clin Oncol. 2000 Jun;23(3):263-6 [10857890.001]
  • [Cites] Nutr Cancer. 2000;37(1):36-40 [10965517.001]
  • [Cites] Intensive Care Med. 2002 Sep;28(9):1294-300 [12209280.001]
  • [Cites] Am J Surg. 1998 Oct;176(4):335-8 [9817250.001]
  • [Cites] Stroke. 2001 Apr;32(4):917-24 [11283392.001]
  • [Cites] Oncology. 2000 Nov;59(4):296-301 [11096341.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Apr;27(4):443-9 [12664077.001]
  • [Cites] J Pain Symptom Manage. 1997 Apr;13(4):220-32 [9136233.001]
  • [Cites] J Pain Symptom Manage. 2000 Aug;20(2):93-103 [10989247.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):448-54 [9971870.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2526-31 [10375098.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2077-82 [7535184.001]
  • [Cites] Curr Oncol Rep. 2002 May;4(3):250-5 [11937016.001]
  • (PMID = 17235502.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


63. Smith BD, Smith GL, Cooper DL, Wilson LD: The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol; 2005 May 20;23(15):3390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry.
  • PURPOSE: Three classification and prognostic systems exist for primary cutaneous B-cell lymphoma (PCBCL).
  • Group IB included diffuse large B-cell histology involving favorable skin sites (head/neck, arm).
  • Group II included diffuse large B-cell histology involving unfavorable skin sites (trunk, legs, disseminated) or immunoblastic large B-cell histology involving favorable skin sites.
  • Group III included immunoblastic large B-cell histology involving unfavorable skin sites.
  • [MeSH-major] Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Registries. Risk Assessment. SEER Program. Sensitivity and Specificity. Sex Distribution. Survival Analysis. World Health Organization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Oct 1;23(28):7246-8 [16192622.001]
  • (PMID = 15908651.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM07205
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Liu XH, Bai CG, Xie Q, Feng F, Xu ZY, Ma DL: Prognostic value of KIT mutation in gastrointestinal stromal tumors. World J Gastroenterol; 2005 Jul 7;11(25):3948-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) Tumor size, PCNA index, mitotic cell number, presence of necrosis, microscopic invasion to adjacent tissues, recurrence and distant metastasis among mutation-positive and mutation-negative GISTs were significantly different.
  • [MeSH-minor] Adult. Female. Gene Frequency. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991300.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4504903
  •  go-up   go-down


65. Kestler MH, Gardner EM, Cohn DL: Hepatic non-Hodgkin's lymphoma with lactic acidosis in HIV-infected patients: report of 2 cases. J Int Assoc Physicians AIDS Care (Chic); 2010 Sep-Oct;9(5):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic non-Hodgkin's lymphoma with lactic acidosis in HIV-infected patients: report of 2 cases.
  • We report 2 patients with HIV-associated non-Hodgkin's lymphoma with massive hepatic involvement and lactic acidosis.
  • [MeSH-major] Acidosis, Lactic / etiology. Liver Neoplasms / complications. Lymphoma, AIDS-Related / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739590.001).
  • [ISSN] 1545-1097
  • [Journal-full-title] Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
  • [ISO-abbreviation] J Int Assoc Physicians AIDS Care (Chic)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Vogl DT, Glatstein E, Carver JR, Schuster SJ, Stadtmauer EA, Luger S, Nasta SD, Porter DL, Elstrom R, Tsai DE: Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk Lymphoma; 2005 Sep;46(9):1313-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking.
  • Of twenty other patients in our practice who received gemcitabine for refractory lymphoma without developing pericardial effusion, none had received prior direct radiation to the heart.
  • Although gemcitabine-based regimens have clear efficacy in refractory lymphoma, prior mediastinal radiation without subcarinal blocking may be a relative contraindication, especially in the presence of pericardial abnormalities on echocardiography.
  • [MeSH-minor] Adult. Female. Heart / radiation effects. Humans. Lymphoma / drug therapy. Lymphoma / radiotherapy. Male. Mediastinum / radiation effects. Middle Aged. Radiation Injuries / etiology

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109609.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


67. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA: Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol; 2010 Feb 10;28(5):773-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
  • PURPOSE HIV-infected persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in the era of effective HIV therapy.
  • PATIENTS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed NHL and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected, lymphoma-free controls who had available stored prediagnostic blood samples.
  • Results The kappa and lambda FLCs were both significantly higher in patients (eg, in 2- to 5-year window: median kappa, 4.24 v 3.43 mg/dL; median lambda, 4.04 v 3.09 mg/dL) and strongly predicted NHL in a dose-response manner up to 2 to 5 years before diagnosis/selection (eg, NHL risk 3.76-fold higher with kappa concentration at least 2.00 times the upper limit of normal, and 8.13-fold higher with lambda concentration at least 2.00 times the upper limit of normal compared with normal levels).
  • CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Adult. B-Lymphocytes / immunology. B-Lymphocytes / virology. Case-Control Studies. Female. Humans. Logistic Models. Lymphocyte Activation. Male. Monoclonal Gammopathy of Undetermined Significance / immunology. Monoclonal Gammopathy of Undetermined Significance / virology. Odds Ratio. Predictive Value of Tests. Prospective Studies. Risk Assessment. Risk Factors. Time Factors. Up-Regulation

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]
  • [Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Curr HIV Res. 2004 Jan;2(1):11-21 [15053337.001]
  • [Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1548-63 [15470219.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]
  • [Cites] JAMA. 1987 Jan 16;257(3):331-4 [3491911.001]
  • [Cites] Clin Chem. 1987 Sep;33(9):1697-8 [3621592.001]
  • [Cites] Clin Chem. 1989 Feb;35(2):338-9 [2914402.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] Br J Haematol. 1993 May;84(1):151-5 [8101720.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2150-6 [9447834.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):296-300 [15688390.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] Haemophilia. 2005 Sep;11(5):516-28 [16128897.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1198-205 [17029142.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1815-26 [19339714.001]
  • (PMID = 20048176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA 62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  • [Other-IDs] NLM/ PMC2834393
  •  go-up   go-down


68. Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J, GESIDA 44/04 SIMPATAZ Study Group: Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Med; 2010 Oct 1;11(9):545-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients underwent a routine physical examination, and data were collected on HIV RNA levels, CD4 cell counts, liver function, lipid parameters, adverse reactions, adherence to treatment and patient satisfaction.
  • The study drug was discontinued early by 25 patients (14%), two of whom discontinued as a result of adverse events (Hodgkin lymphoma and vomiting).
  • Hyperbilirubinaemia >3 mg/dL and increased alanine aminotransferase levels>200 IU/L were observed in 38.5% and 4.4% of patients, respectively.
  • Median changes from baseline to month 12 in total cholesterol, triglycerides and low-density lipoprotein cholesterol were -13 mg/dL (-7%; P<0.0001), -19 mg/dL (-13%; P<0.0001) and -7 mg/dL (-6%; P=0.021), respectively.
  • [MeSH-minor] Adult. Atazanavir Sulfate. CD4 Lymphocyte Count. Cholesterol, HDL / blood. Cholesterol, LDL / blood. Fasting. Female. Hepatitis, Viral, Human / complications. Humans. Male. Medication Adherence. Middle Aged. Patient Satisfaction. Prospective Studies. Transaminases / blood. Treatment Outcome. Triglycerides / blood. Viral Load

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345884.001).
  • [ISSN] 1468-1293
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / HIV Protease Inhibitors; 0 / Oligopeptides; 0 / Pyridines; 0 / Triglycerides; 4MT4VIE29P / Atazanavir Sulfate; EC 2.6.1.- / Transaminases; O3J8G9O825 / Ritonavir
  • [Investigator] Rubio R; Carmena J; Vicent R; Ricart MC; Asensi V; Moreno A; Cartón JA; Maradona JA; Telentí M; Echevarría S; Fariñas MC; García JD; García JP; Flores J; Ribera E; Díaz M; Ocaña I; Azuaje C; de Zárraga MA; Tuya MJ; Cembellín M; Ocampo A; Miralles C; López AM; Rodríguez da Silva A; García-Alcalde ML; Sepúlvedal MA; Cuadra F; Layo J; Yuste RM; Il Mariño A; Trasancos V; Alvarez H; Minguez C; Roca B; Usó J; Soler JA; Alvarez H; Minguez C; Roca B; Usó J; Soler JA; Boix V; Portilla J; Giner L; Merino E; Reus S; Prieto A; Losada E; Antela A; Blázquez RM; Espinosa FJ; Carpena I; Barberá JR; Geijó MP; Rosa Herranz C; Barrufet P; Force L; Cano A; Muñoz MA; Peralta FG; Masabeu A; Pedrol E; Deig E; García J; Martínez O; Vera F; Rodríguez M; Carcaba V; Orti AJ; Navarro V; Gregori Colomé J; González E; Galindo MJ; Guix J; Alcácer F; Homar Borrás F; Bassa A; Cifuentes MC; Payeras A; González-Garcia J; Moyano B; Esteban H; Serrano L; Mahillo B
  •  go-up   go-down


69. Arumugam GP, Sundravel S, Shanthi P, Sachdanandam P: Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab; 2006;24(3):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median calcium value was 13.6 mg/dl (range, 11.7-15.8).
  • All the patients were treated with hydration, and 6 patients, whose calcium level was above 13.6 mg/dl, were treated with a moderate dose of gallium nitrate (200 mg/m(2) per kg) for 5 consecutive days, they achieved normocalcemia and continued with tamoxifen.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bone Neoplasms / secondary. Estrogen Receptor Modulators / adverse effects. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1451-9 [1021226.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):283-96 [12050020.001]
  • [Cites] Ann Intern Med. 1990 Dec 1;113(11):847-51 [2240900.001]
  • [Cites] Cancer Treat Rep. 1983 Jan;67(1):101-2 [6616491.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):603-5 [12002765.001]
  • [Cites] Oncology (Williston Park). 1995 Sep;9(9):877-86, 889-90; discussion 892-4 [8562327.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):1013 [717984.001]
  • [Cites] Endocrinology. 1978 Nov;103(5):1742-51 [748014.001]
  • [Cites] Oncology. 1973;28(2):126-37 [4270379.001]
  • [Cites] Ann Intern Med. 1978 Jan;88(1):69-77 [339802.001]
  • [Cites] Union Med Can. 1978 Oct;107(10):964-5 [705958.001]
  • [Cites] JAMA. 1979 Jun 8;241(23):2506-7 [439333.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1431-5 [798626.001]
  • [Cites] JAMA. 1978 Dec 8;240(24):2644-6 [712982.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):61-6 [3814476.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1839-41 [230894.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 5):3-9 [2185551.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):491-8 [2713238.001]
  • [Cites] Ann Intern Med. 1990 Apr 1;112(7):499-504 [2138442.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):423-4 [686559.001]
  • [Cites] Pharmacol Rev. 1998 Dec;50(4):665-82 [9860806.001]
  • [Cites] Cancer. 1981 Jun 15;47(12):2803-6 [7260871.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2383-5 [7296487.001]
  • [Cites] Oncology. 2001;60(2):123-6 [11244326.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1106-12 [2320080.001]
  • (PMID = 16622738.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; CH46OC8YV4 / Gallium; VRA0C6810N / gallium nitrate
  •  go-up   go-down


70. Hunault-Berger M, Tanguy-Schmidt A, Rachieru P, Lévy V, Truchan-Graczyk M, Francois S, Gardembas-Pain M, Dib M, Foussard C, Piard N, Godon A, Solal-Celigny P, Ifrah N: rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant; 2005 May;35(9):903-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study.
  • To decrease red blood cell (RBC) transfusion requirements during high-dose therapy (HDT) for hematological malignancies, we conducted a pilot study to assess the effect of recombinant human erythropoietin (rHuEpo) given during chemotherapy before HDT and autologous peripheral stem-cell transplantation (APSCT).
  • The transfusion histories of 15 HDT and APSCT for hematological disease performed in 11 consecutive patients who received rHuEpo (10 000 U subcutaneously three times/week) were compared to those of 22 HDT and ASCT performed in 17 consecutive historical controls matched for hematological parameters. rHuEpo increased the hemoglobin (Hb) level from 10.3+/-2.3 g/dl at diagnosis to 12.9+/-2.2 g/dl at the time of HDT in 11 patients; no major adverse effects occurred.
  • [MeSH-major] Erythrocyte Transfusion. Erythropoietin / administration & dosage. Lymphoma, Mantle-Cell / therapy. Multiple Myeloma / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged. Pilot Projects. Recombinant Proteins. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765111.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


71. He YF, Wei W, Sun ZM, Ji CS, Wang G, Chen MP, Hu CL, Hu B: Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma. Adv Ther; 2007 May-Jun;24(3):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma.
  • Presented here is the first reported case of natural killer (NK)/T-cell lymphoma associated with lactic acidosis (LA) and hypoglycemia.
  • LA and hypoglycemia are rare complications of non-Hodgkin's lymphoma.
  • A 28-year-old male patient with NK/T-cell lymphoma had a relapse after 14 mo of initial remission and was admitted to the hospital because of altered mental status.
  • He developed severe LA (pH, 7.17; lactate, 11.2 mmol/L) and hypoglycemia (42 mg/dL) that was resistant to sodium bicarbonate and glucose infusions.
  • The case described here indicates that non-Hodgkin's lymphoma-induced LA portends a poor prognosis.
  • [MeSH-major] Acidosis, Lactic / etiology. Hypoglycemia / etiology. Killer Cells, Natural. Lymphoma, T-Cell / complications. Nose Neoplasms / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male


72. Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R: Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk; 2010 Feb;10(1):E10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only 43 patients (48%) had an involved sFLC > or = 10 mg/dL (which is considered evaluable by the IMWG), of which 14 had PR, 8 had SD, 18 had PD, and 3 were inevaluable.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Creatinine / blood. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223721.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; AYI8EX34EU / Creatinine
  •  go-up   go-down


73. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL, Canadian MS BMT Study Group: Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology; 2006 Jun 27;66(12):1935-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.
  • The authors measured brain atrophy in nine patients undergoing immunoablation and autologous hematopoietic stem cell transplantation for multiple sclerosis.
  • A patient with non-CNS lymphoma showed comparable acute brain atrophy after analogous therapy.
  • [MeSH-major] Brain / pathology. Brain Diseases / diagnosis. Brain Diseases / etiology. Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Multiple Sclerosis / surgery. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Atrophy / diagnosis. Atrophy / etiology. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome


74. Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA, Toze CL: Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant; 2008 Nov;42(9):601-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.
  • Outcome is poor with conventional therapy for relapsed transformed non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Living Donors. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Survival Rate. Transplantation Conditioning / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695664.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O: Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 May;54(5):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-five newly diagnosed children and adolescents aged 0.4-21 years with ALL or lymphoblastic lymphoma were retrospectively evaluated for lipid abnormalities.
  • RESULTS: Prior to treatment, mean cholesterol level was 149 +/- 50 mg/dl, and increased to maximal level 274 +/- 124 mg/dl during treatment.
  • Mean TG level during treatment was 459 +/- 526 mg/dl (range 54-3,009).
  • Twelve patients (28%) had TG levels <200 mg/dl, 18 (43%) had 200-400 mg/dl, 3 (7%) had 400-600 mg/dl, 4 (10%) between 600 and 1,000 mg/dl, and 5 (12%) patients had >1,000 mg/dl.
  • One of the 12 patients with TG >400 mg/dl developed left saggital sinus thrombosis and left frontal lobe infarct.
  • TG level at the time of the event was 2,640 mg/dl.
  • None of the five patients with TG levels >1,000 mg/dl developed pancreatitis.
  • Children with TG levels between 400 and 600 mg/dl were treated by fasting.
  • Fibrates and heparin were added to those with levels >600 mg/dl.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Drug Monitoring. Hypercholesterolemia / prevention & control. Hypertriglyceridemia / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clofibric Acid / administration & dosage. Diet, Carbohydrate-Restricted. Diet, Fat-Restricted. Fasting. Female. Humans. Hypolipidemic Agents / administration & dosage. Infant. Israel / epidemiology. Male. Remission Induction. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063421.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypolipidemic Agents; 53PF01Q249 / Clofibric Acid; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


76. Cesana C, Barbarano L, Miqueleiz S, Lucchesini C, Ricci F, Varettoni M, Filippini D, Lazzarino M, Morra E: Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma; 2005 Mar;5(4):261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At a median of 62 months (12-195 months), 8 cases of IgM-RDs (8.4%) evolved to overt Waldenstrom's macroglobulinemia (n = 6), 1 case to non-Hodgkin's lymphoma, and 1 case to B-cell chronic lymphocytic leukemia.
  • At univariate analysis, male sex (P = 0.02), IgM level > or = 3 g/dL (P < 0.0001), detectable Bence Jones proteinuria (P = 0.0005), lymphocytosis (P = 0.049), and high erythrocyte sedimentation rate (P = 0.003) significantly correlated with the evolution risk.
  • Age, blood cell counts, b2-microglobulin level, degree of marrow lymphoplasmacytic infiltration, type of cryoglobulinemia, and hepatitis C virus positivity did not correlate with transformation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Sedimentation. Cell Transformation, Neoplastic. Female. Follow-Up Studies. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prognosis. Risk Factors. Sex Factors. Treatment Outcome. Waldenstrom Macroglobulinemia / etiology. Waldenstrom Macroglobulinemia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794861.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


77. Lasmar EP, Coelho LG, Lasmar MF, Lasmar LF, Lima PV, Nogueira AF: Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report. Transplant Proc; 2009 Apr;41(3):959-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report.
  • The treatment of B-cell non-Hodgkin lymphoma, the most common posttransplant lymphoproliferative disorder, is not well defined.
  • Herein we have reported a case of gastric mucosa-associated lymphoid tissue (MALT) lymphoma with rapid, persistent, and complete remission after conversion of the immunosuppression from cyclosporine (CsA) to sirolimus (SRL).
  • A 42-year-old woman underwent renal transplantation in 1992 with no major abnormalities until 2006 when a gastroscopy performed to investigate dyspeptic symptoms showed a mixed MALT gastric lymphoma (with low- and high-grade components) associated with the presence of Helicobacter pylori infection.
  • Currently, the patient has no complaints, displaying a creatinine value of 1.8 mg/dL and a hemoglobin of 9.4 mg/dL using SRL and ibersatan.
  • In conclusion, our case of gastric MALT lymphoma in a renal transplant patient displayed a complete remission after alteration of the immunosuppressive scheme with the introduction of SRL.
  • [MeSH-major] Azathioprine / adverse effects. Cyclosporine / adverse effects. Gastric Mucosa / pathology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / immunology. Lymphoma, B-Cell, Marginal Zone / complications. Sirolimus / therapeutic use. Stomach Neoplasms / complications
  • [MeSH-minor] Adult. Female. Helicobacter Infections / complications. Helicobacter pylori. Humans. Living Donors


78. Inamoto Y, Teramoto T, Shirai K, Tsukamoto H, Sanda T, Miyamura K, Yamamori I, Hirabayashi N, Kodera Y: Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. Int J Hematol; 2005 Nov;82(4):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation.
  • A 55-year-old woman with Ph-negative acute lymphoblastic leukemia in primary induction failure received allogeneic peripheral blood stem cell transplantation from her HLA-compatible sister.
  • Pseudohyponatremia developed due to extreme hypercholesterolemia of 4091 mg/dL accompanied by lipoprotein X and lipoprotein Y.
  • [MeSH-major] Hypercholesterolemia / etiology. Hyponatremia / etiology. Lipase / metabolism. Liver / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] ABO Blood-Group System. Adult. Blood Group Incompatibility. Female. Humans. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Clin Lab Sci. 1998 Dec;35(6):547-72 [9885775.001]
  • [Cites] Gastroenterology. 1985 Dec;89(6):1266-78 [4054519.001]
  • [Cites] Acta Med Scand. 1986;219(5):435-47 [3739751.001]
  • [Cites] Pathology. 1986 Jan;18(1):158-9 [3523399.001]
  • [Cites] Bone Marrow Transplant. 1996 Aug;18(2):457-9 [8864464.001]
  • [Cites] J Lipid Res. 2004 Nov;45(11):2116-22 [15314101.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(1):85-9 [15531904.001]
  • [Cites] Clin Liver Dis. 1999 Aug;3(3):651-68, x [11291243.001]
  • [Cites] Atherosclerosis. 1997 Jun;131(2):203-10 [9199273.001]
  • [Cites] Gastroenterology. 1990 May;98(5 Pt 1):1351-7 [2323525.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1465-9 [14534340.001]
  • [Cites] Atherosclerosis. 2000 Apr;149(2):395-401 [10729390.001]
  • [Cites] Hepatology. 1985 Mar-Apr;5(2):286-92 [3920136.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1248-60 [816809.001]
  • [Cites] Nutrition. 1997 May;13(5):417-21 [9225333.001]
  • [Cites] Metabolism. 1991 Oct;40(10):1052-6 [1943731.001]
  • [Cites] Can J Cardiol. 2000 Apr;16(4):505-11 [10787466.001]
  • [Cites] Acta Med Okayama. 1979 Aug;33(4):269-85 [227230.001]
  • [Cites] Atherosclerosis. 1982 Nov;45(2):161-79 [6961921.001]
  • [Cites] Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):807-32 [2082907.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S22-4 [10412730.001]
  • [Cites] Transplantation. 1994 May 27;57(10):1479-83 [8197611.001]
  • [Cites] Metabolism. 1985 Sep;34(9):832-5 [4033424.001]
  • [Cites] Eur J Clin Invest. 1977 Dec;7(6):557-62 [415876.001]
  • [Cites] Clin Chim Acta. 1996 Jan 15;244(1):1-15 [8919198.001]
  • [Cites] J Immunol Methods. 2000 Feb 21;235(1-2):41-51 [10675756.001]
  • (PMID = 16298832.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABO Blood-Group System; EC 3.1.1.3 / Lipase
  •  go-up   go-down


79. Sipahimalani P, Spinelli JJ, MacArthur AC, Lai A, Leach SR, Janoo-Gilani RT, Palmquist DL, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR: A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. Int J Cancer; 2007 Nov 1;121(9):1967-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma.
  • Mutations in this gene cause the autosomal recessive syndrome ataxia telangiectasia (AT), an attribute of which is an increased risk of cancer, particularly lymphoma.
  • We have undertaken a population-based case/control study to assess the influence of genetic variation in ATM on the risk of non-Hodgkin lymphoma (NHL).
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Genotype. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Mutation / genetics


80. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM: High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol; 2005 Nov 1;23(31):7994-8002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
  • PURPOSE: To determine the incidence of second malignancies among patients with Hodgkin's lymphoma (HL) treated with autologous hematopoietic stem cell transplantation (AHSCT) compared with patients receiving conventional therapy alone and to identify potential risk factors for their occurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Incidence. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Male. Middle Aged. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / etiology. Retrospective Studies. Risk Factors. Transplantation, Autologous


81. Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS: Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol; 2006 Apr 10;24(11):1712-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Vascular endothelial growth factor antisense (VEGF-AS) is an antisense oligonucleotide that targets VEGF, inhibiting angiogenesis and tumor cell proliferation.
  • Clinical responses included complete remission in one patient with AIDS-Kaposi's sarcoma, a mixed but dramatic response in one patient with cutaneous T-cell lymphoma, and prolongation of progression-free survival compared with that obtained on the immediate prior regimen in six patients (12%) with renal cell, bronchoalveolar, small cell lung, thyroid, and ovarian carcinomas, and chondrosarcoma, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Vascular Endothelial Growth Factor C / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA 79218
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


82. Ornstein DL, Bifulco CB, Braddock DT, Howe JG: Histopathologic and molecular aspects of CD56+ natural killer/ T-cell lymphoma of the testis. Int J Surg Pathol; 2008 Jul;16(3):291-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic and molecular aspects of CD56+ natural killer/ T-cell lymphoma of the testis.
  • Primary nasal-type natural killer/T-cell lymphoma of the testis is a rare malignancy.
  • In this article, the authors report on the comprehensive histopathologic, immunohistochemical, and molecular analysis of a case of primary testicular nasal-type natural killer/T-cell lymphoma, and review the features of 16 previously reported patients.
  • The investigation carried out in this study indicates that the testicular nasal-type natural killer/T-cell lymphomas occur at a younger age than their B-cell counterparts, express cytoplasmic CD3 and surface CD56, and consistently show an infection by Epstein-Barr virus.
  • These tumors have variable expression of T-cell antigens other than cytoplasmic CD3 and may show monoclonal rearrangement of T-cell receptor genes.
  • Testicular natural killer/T-cell lymphomas of nasal type invariably follow an aggressive clinical course.
  • [MeSH-major] Antigens, CD56 / analysis. Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. In Situ Hybridization. Male. Orchiectomy. RNA, Viral / analysis. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573785.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


83. Ogawa T, Kammori M, Tsuji E, Kanauchi H, Kurabayashi R, Terada K, Mimura Y, Kaminishi M: Preoperative evaluation of thyroid pathology in patients with primary hyperparathyroidism. Thyroid; 2007 Jan;17(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean preoperative calcium level was 11.2mg/dL, and the mean intact parathyroid hormone level was 206 pg/mL.
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Calcium / blood. Female. Humans. Incidence. Incidental Findings. Lymphatic Metastasis. Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma / surgery. Lymphoma / ultrasonography. Middle Aged. Parathyroid Hormone / blood. Parathyroidectomy. Preoperative Care. Prevalence

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274751.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


84. Sarma PK, Chowhan AK, Agrawal V, Agarwal V: Fine needle aspiration cytology in HIV-related lymphadenopathy: experience at a single centre in north India. Cytopathology; 2010 Aug;21(4):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fungal infection and non-Hodgkin lymphoma (NHL) were seen in two patients each.
  • Both patients with NHL had CD4 counts below 100/dl.
  • Necrotizing lymphadenitis and granulomatous lymphadenitis were significantly associated with CD4 counts below and above 200/dl, respectively (P = 0.0002).
  • [MeSH-minor] Adolescent. Adult. Aged. Bacillus / cytology. Biopsy, Fine-Needle. CD4 Lymphocyte Count. Child. Female. Humans. India. Male. Middle Aged. Sputum / microbiology. Tuberculin Test. Young Adult


85. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood; 2006 Feb 15;107(4):1325-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases.
  • Ex vivo T-cell activation might overcome disease-induced anergy and augment GVT activity.
  • Eight patients achieved complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myelogenous leukemia (AML), 1 with chronic lymphocytic leukemia (CLL), and 1 of 2 with non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Antigens, CD28 / blood. Antigens, CD8 / blood. Leukemia / therapy. Lymphocyte Transfusion / adverse effects. Lymphoma / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / blood. Child. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269610.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD8
  •  go-up   go-down


86. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Luo XL: [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):771-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
  • OBJECTIVE: To study the histology, immunophenotype and differential diagnosis of T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • METHODS: A review of 245 cases of so-called Hodgkin lymphoma diagnosed during the period from 1980 to 2000 in 3 hospitals in Guangzhou, 8 cases were reclassified as TCRBCL, according to the 2001 World Health Organization classification of lymphoid neoplasms.
  • Immunohistochemical studies were performed on paraffin-embedded tissue by SP technique in order to study the immunophenotype of the large neoplastic cells (CD20, CD79a, CD3, CD45RO, CD15, CD30, CD10, bcl-6 and EMA) and background non-neoplastic cells (CD3, CD8, CD20, CD45RO, CD79a, CD57, CD68, CD21, CD35, cyclin D1, TIA-1).
  • Histologically, scattered atypical large neoplastic cells were seen in a background of small lymphocytes and sometimes histiocytes.
  • The large cells exhibited CD20+, CD79a+, EMA+, CD15- and CD30- phenotype.
  • The histiocytic cells were CD68-positive; and CD21 and CD35-positive follicular dendritic cell meshworks were absent.
  • CONCLUSIONS: TCRBCL is a rare subtype of lymphoma, with distinctive histology and immunophenotype.
  • The above features are helpful in delineating this entity from Hodgkin lymphoma, reactive lymphoid hyperplasia and lymphomatoid granulomatosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Child. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545182.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Mucin-1
  •  go-up   go-down


87. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperglycemic adult ALL patients have shorter remissions, more infections, and increased mortality.
  • Infectious outcomes during the first year of therapy were compared in three groups patients based on blood glucose concentrations during induction therapy: euglycemic (<140 mg/dl), mild hyperglycemic (MH) (140-199 mg/dl) and overt hyperglycemic (OH) (blood glucose >200 mg/dl).
  • [MeSH-major] Hyperglycemia / complications. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18523991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


88. Yel L, Ramanuja S, Gupta S: Clinical and immunological features in IgM deficiency. Int Arch Allergy Immunol; 2009;150(3):291-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Through a retrospective chart review, we investigated the clinical and immunological features of 15 symptomatic adult IgM-deficient patients who were referred to our immunology clinics over a 4-year period.
  • On initial evaluation, 12 patients (80%) presented with susceptibility to infections, 5 (33%) had atopic manifestations such as asthma and allergic rhinitis, 3 (20%) had both infections and atopy, 4 patients (28%) had fibromyalgia-like symptoms, 3 (20%) had autoimmune manifestations, and 1 patient had lymphoma.
  • The mean serum IgM level was 27.4 mg/dl (range 14-39).
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / immunology. Diagnosis, Differential. Female. Humans. Immunity, Humoral. Immunoglobulin M / blood. Immunoglobulin M / deficiency. Immunoglobulins, Intravenous / therapeutic use. Male. Middle Aged. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19494527.001).
  • [ISSN] 1423-0097
  • [Journal-full-title] International archives of allergy and immunology
  • [ISO-abbreviation] Int. Arch. Allergy Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


89. Birgegård G, Gascón P, Ludwig H: Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol; 2006 Nov;77(5):378-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.
  • OBJECTIVES: Until recently, no prospective epidemiologic survey of lymphoma and multiple myeloma (L/MM) in European cancer patients had been conducted; furthermore, data on prevalence, incidence, and treatment patterns of L/MM were limited or unavailable.
  • Anemia prevalence during ECAS was 72.9% (MM, 85.3%; non-Hodgkin's lymphoma, 77.9%; Hodgkin's disease, 57.4%); incidence in chemotherapy patients was 55.4%.
  • Only 47.3% of patients anemic any time during ECAS received anemia treatment; overall Hb nadir for initiating treatment was 8.9 g/dL (epoetin, 9.5 g/dL; transfusion, 8.2 g/dL).
  • [MeSH-major] Anemia / epidemiology. Lymphoma / epidemiology. Multiple Myeloma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Europe. Evaluation Studies as Topic. Female. Hemoglobins. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prevalence. Quality of Life. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Aug;12(8):1281-7 [9697885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1047-56 [9719114.001]
  • [Cites] Med Oncol. 1998 Aug;15 Suppl 1:S29-34 [9785334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):172-9 [11328297.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2865-74 [11387359.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2875-82 [11387360.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):7-14 [11395846.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1617-23 [11527686.001]
  • [Cites] Hematol J. 2002;3(3):121-30 [12111647.001]
  • [Cites] Wien Med Wochenschr. 2002;152(13-14):334-42 [12168517.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1109-15 [9834824.001]
  • [Cites] Haematologica. 1998 Nov;83(11):993-7 [9864919.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:55-69 [15591423.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1797-802 [15479721.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2597-605 [15452188.001]
  • [Cites] Oncology. 2006;70(1):34-48 [16493206.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2303-20 [12239138.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:27-30 [12626786.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):386-93 [12877665.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):394-403 [12877666.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1072-9 [12942577.001]
  • [Cites] Hematol Oncol. 2003 Dec;21(4):169-80 [14735555.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2201-16 [15454245.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2293-306 [15454256.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1618-26 [1651993.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6 [9671330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):54-7 [9671332.001]
  • (PMID = 17044835.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC1618958
  •  go-up   go-down


90. Frobisher C, Lancashire ER, Winter DL, Taylor AJ, Reulen RC, Hawkins MM, British Childhood Cancer Survivor Study: Long-term population-based divorce rates among adult survivors of childhood cancer in Britain. Pediatr Blood Cancer; 2010 Jan;54(1):116-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term population-based divorce rates among adult survivors of childhood cancer in Britain.
  • BACKGROUND: Previously from the British Childhood Cancer Survivor Study (BCCSS) it was seen that adult survivors of childhood cancer were less likely to marry than the general population.
  • However, the survivors overall (OR (95% CI): 0.82 (0.72-0.94)), and separately for those diagnosed with non-Hodgkin lymphoma (OR (95% CI): 0.55 (0.34-0.89)) and leukaemia (OR (95% CI): 0.70 (0.52-0.95)), were less likely to be currently divorced or separated than the general population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Great Britain / epidemiology. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Risk Factors. Survival Rate. Survivors. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Divorce.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19774635.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Hawkins M; Jenkinson H; Jenney M; Lancashire E; Pritchard-Jones K; Stevens M; Stiller C; Sugden E; Toogood A; Wallace H
  •  go-up   go-down


91. Sattar T, Griffeth LK, Latifi HR, Glass J, Munker R, Lilien DL: PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas. J La State Med Soc; 2006 Jul-Aug;158(4):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant non-Hodgkin lymphomas (NHLs) are commonly staged according to the Ann Arbor staging system developed for Hodgkin's lymphoma.
  • In the subtype of high grade NHL diffuse large B cell lymphoma, upstaging by PET appears to be clinically relevant as a marker for a more aggressive tumor.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022364.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Yang S, Jun M, Hong-Li Z, Jian-Min W, Chun W, Lu-Gui Q, Yong-Qiang Z, Jun Z, Jian H, Zhi-Xiang S: A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol; 2008 Sep;88(2):139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
  • The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL).
  • The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing > or = 2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Female. Ferritins / blood. Humans. Iron / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Multiple Myeloma / complications. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells. 1995 Jan;13(1):32-7 [7719246.001]
  • [Cites] Ann Oncol. 1993 Feb;4(2):161-7 [8448084.001]
  • [Cites] N Engl J Med. 1990 Jun 14;322(24):1693-9 [2342535.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):79-89 [9450795.001]
  • [Cites] J Am Soc Nephrol. 1994 Aug;5(2):177-85 [7993997.001]
  • [Cites] Cancer Prev Control. 1997 Aug;1(3):241-8 [9765749.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 8):29-35 [1615337.001]
  • [Cites] Stem Cells. 1993 Sep;11(5):348-55 [8241947.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1109-15 [9834824.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Dec;8(6):1223-53 [7860446.001]
  • [Cites] Int J Hematol. 1992 Apr;55(2):197-203 [1511168.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2486-94 [12011126.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):81-6 [9458299.001]
  • [Cites] Nephrol Dial Transplant. 1999;14 Suppl 2:85-92 [10334673.001]
  • [Cites] Int J Oncol. 1993 Dec;3(6):1121-6 [21573482.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] Med Oncol. 1998 Aug;15 Suppl 1:S29-34 [9785334.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):23-6 [9671326.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2675-82 [8639883.001]
  • (PMID = 18629603.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / epoetin beta; 11096-26-7 / Erythropoietin; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  •  go-up   go-down


93. Langner-Wegscheider BJ, ten Dam-van Loon N, Mura M, Faridpooya K, de Smet MD: Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis. Can J Ophthalmol; 2010 Apr;45(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Two SLE patients and one patient post chemotherapy for a non Hodgkin's lymphoma presented with myelosuppression and persistent cytomegalovirus retinitis despite systemic ganciclovir therapy.
  • METHODS: Patients were treated with 100 microL of intravitreal ganciclovir (4 mg/dL), initially given weekly.
  • Fluorescence-activated cell sorting analysis in one patient showed the presence of low CD4 and CD8 while treated with systemic ganciclovir, which improved with intravitreal treatment.


94. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytological Techniques. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O, Sandrock D, Munz DL, Glass B, Thiel E, Blau IW: Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma; 2006 Jan;47(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
  • Radioimmunotherapy (RIT) of relapsed lymphoma is gaining increasing importance.
  • Especially the commercially available anti-CD20 antibody 90Y-ibritumomab tiuxetan is currently under investigation in various trials including dose escalation and autologous hematopoietic progenitor cell support.
  • It is not clear, however, whether the implementation of this radiolabeled antibody into another treatment option for relapsed or poor risk lymphoma patients-allogeneic hematopoietic cell transplantation-interferes with or delays successful engraftment.
  • This study reports encouraging results with 2 relapsed lymphoma patients (1 transformed marginal zone lymphoma and 1 mantle cell lymphoma) who underwent allogeneic hematopoietic cell transplantation from HLA-matched donors.
  • Thus, the incorporation of radioimmunotherapy into allogeneic transplant protocols combines established modalities with proven anti-lymphoma activity and, hence, offers an attractive new therapeutic option for relapsed lymphoma patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Mantle-Cell / therapy. Radioimmunotherapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease Progression. Follow-Up Studies. Humans. Male. Recurrence. Remission Induction. Retrospective Studies. Time Factors. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Yttrium Radioisotopes / administration & dosage. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321828.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


96. Zhao XR, Ma DL: [Expression of Oct2 and its significance in lymphoma diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Oct2 and its significance in lymphoma diagnosis].
  • OBJECTIVE: To investigate the specificity and sensitivity of Oct2 protein expression in lymphoma cells and its significance in diagnosis and classification of lymphoma.
  • METHODS: Formalin-fixed and paraffin-embedded materials from 129 cases of lymphoma and 10 cases of reactive lymphoid hyperplasia (RLH) were studied by EnVision immunohistochemistry for Oct2 protein.
  • It was diffusely expressed in B-cell lymphoma cells.
  • 97.7% cases (85/87) of B-cell lymphoma and 3.8% cases (1/26) of T-cell lymphoma were positive for Oct2 protein.
  • In comparison, the expression rates for CD20 and CD79alpha in B-cell lymphomas were 90.8% (79/87) and 84.7% (61/72) respectively.
  • The expression rates of Oct2 protein in nodular lymphocyte-predominant Hodgkin lymphoma and classic Hodgkin lymphoma were 3/3 and 46.2% (6/13) respectively.
  • CONCLUSION: As a relatively sensitive and specific marker for B cells, Oct2 can serve as a useful antibody for the diagnosis and differential diagnosis of lymphoma.
  • [MeSH-major] Lymphoma / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / metabolism. Octamer Transcription Factor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Child. Diagnosis, Differential. Female. Germinal Center / metabolism. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Male. Middle Aged. Pseudolymphoma / diagnosis. Pseudolymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185500.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / CD79A protein, human; 0 / Octamer Transcription Factor-2
  •  go-up   go-down


97. Alge DL, Zhou D, Adams LL, Wyss BK, Shadday MD, Woods EJ, Gabriel Chu TM, Goebel WS: Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. J Tissue Eng Regen Med; 2010 Jan;4(1):73-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All experiments were performed using cells isolated from a single adult Sprague-Dawley rat.
  • Furthermore, while both cell populations formed mineral in vitro, DPSCs had significantly higher alkaline phosphatase activity than BMMSCs after 3 weeks in osteogenic medium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons, Ltd.
  • [Cites] Radiology. 2007 Aug;244(2):514-23 [17562811.001]
  • [Cites] Biol Cell. 2007 Aug;99(8):465-74 [17371295.001]
  • [Cites] J Orthop Res. 2007 Aug;25(8):1029-41 [17469183.001]
  • [Cites] Cell Prolif. 2008 Feb;41(1):1-11 [18211282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13625-30 [11087820.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):364-70 [10931522.001]
  • [Cites] J Cell Biochem. 1999 Dec 1;75(3):424-36 [10536366.001]
  • [Cites] Stem Cells. 2001;19(3):219-25 [11359947.001]
  • [Cites] Bone. 2001 Dec;29(6):532-9 [11728923.001]
  • [Cites] J Dent Res. 2002 Aug;81(8):531-5 [12147742.001]
  • [Cites] Ann Biomed Eng. 2004 Jan;32(1):160-5 [14964731.001]
  • [Cites] Blood. 1980 Aug;56(2):289-301 [6994839.001]
  • [Cites] Int J Dev Biol. 1995 Feb;39(1):273-80 [7626417.001]
  • [Cites] Calcif Tissue Int. 1996 Oct;59(4):265-70 [8781050.001]
  • [Cites] Arch Oral Biol. 2005 Feb;50(2):153-7 [15721143.001]
  • [Cites] Tissue Eng Part A. 2008 Feb;14(2):285-94 [18333781.001]
  • [Cites] Tissue Eng Part C Methods. 2008 Jun;14(2):149-56 [18489245.001]
  • [Cites] Stem Cells Dev. 2008 Aug;17(4):761-73 [18393634.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2342-51 [19129541.001]
  • [Cites] J Bone Miner Res. 2005 Aug;20(8):1394-402 [16007337.001]
  • [Cites] Orthod Craniofac Res. 2005 Aug;8(3):191-9 [16022721.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1531-44 [16236607.001]
  • [Cites] Calcif Tissue Int. 2005 Oct;77(4):212-25 [16193234.001]
  • [Cites] J Cell Physiol. 2006 Mar;206(3):693-701 [16222704.001]
  • [Cites] J Cell Physiol. 2006 Aug;208(2):319-25 [16622855.001]
  • [Cites] J Craniofac Surg. 2006 May;17(3):511-5 [16770190.001]
  • [Cites] Tissue Eng. 2007 Apr;13(4):767-73 [17432951.001]
  • [Cites] Cell Death Differ. 2007 Jun;14(6):1162-71 [17347663.001]
  • [Cites] J Endod. 2007 Jun;33(6):703-8 [17509410.001]
  • [Cites] Cell Biol Int. 2007 Oct;31(10):1191-7 [17524678.001]
  • [Cites] Orthod Craniofac Res. 2007 Aug;10(3):149-60 [17651131.001]
  • (PMID = 19842108.001).
  • [ISSN] 1932-7005
  • [Journal-full-title] Journal of tissue engineering and regenerative medicine
  • [ISO-abbreviation] J Tissue Eng Regen Med
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL075253-05; United States / NHLBI NIH HHS / HL / K08 HL075253; United States / NHLBI NIH HHS / HL / HL075253-05; United States / NCRR NIH HHS / RR / G20 RR023962; United States / NCRR NIH HHS / RR / 1R43RR023962; United States / NCRR NIH HHS / RR / G20 RR023962-01; United States / NCRR NIH HHS / RR / RR023962-01; United States / NHLBI NIH HHS / HL / K08 HL75253
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS177939; NLM/ PMC2830796
  •  go-up   go-down


98. Kraus TS, Sillings CN, Saxe DF, Li S, Jaye DL: The role of CD11c expression in the diagnosis of mantle cell lymphoma. Am J Clin Pathol; 2010 Aug;134(2):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of CD11c expression in the diagnosis of mantle cell lymphoma.
  • Flow cytometric immunophenotyping (FCI) aids in the differentiation of chronic lymphocytic leukemia (CLL) from mantle cell lymphoma (MCL); however, overlapping phenotypes may occur.
  • FCI reports were reviewed for 90 MCL cases (44 patients) and 355 CLL/small lymphocytic lymphoma (SLL) cases (158 patients).
  • CD11c expression is rare in MCL and may aid in differentiation of CD5+ B-cell neoplasms, particularly when small samples limit further ancillary testing.
  • [MeSH-major] Antigens, CD11c / biosynthesis. Biomarkers, Tumor / immunology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Separation. Female. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged


99. Parada MT, Alba A, Sepúlveda C: Everolimus in lung transplantation in Chile. Transplant Proc; 2010 Jan-Feb;42(1):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Eight of 55 lung transplantation patients were switched to everolimus, targeting a (mean drug level of 4.2 ng/dL), in combination with low-dose tacrolimus (mean levels 5.5 ng/dL) and steroids.
  • The Reasons for conversion were: CNI nephropathy (n = 3), BOS (n = 4), and lymphoma (n = 1).
  • In patients with renal dysfunction, serum creatinine had risen from 1.1 to 1.8 mg/dl, but at 3 months after everolimus conversion, they had returned to baseline values, maintaining that level for at least 2 years' follow-up.
  • The patient with lymphoma died 11 months after conversion.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bronchiolitis Obliterans / diagnosis. Chile. Everolimus. Female. Graft Rejection / prevention & control. Humans. Kidney / pathology. Male. Middle Aged. Postoperative Complications / drug therapy. Postoperative Complications / epidemiology. Tacrolimus / adverse effects. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20172343.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


100. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • [MeSH-minor] Adult. Erythema / etiology. Erythema / pathology. Graft vs Tumor Effect. Humans. Male. Recurrence. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement